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ABSTRACT OF DISSERTATION

EXAMINING THE ROLE OF METABOLIC PATHWAYS AS THERAPEUTIC
MODALITIES FOR TRIPLE NEGATIVE BREAST CANCER

Triple negative breast cancer (TNBC) comprises 15-20% of breast
cancers, affects a younger patient population than other subtypes, and is very
aggressive. TNBC is comprised of a diverse group of tumors that have proven
refractory to targeted therapy and can be difficult to treat. Patients generally
receive neoadjuvant chemotherapy (NAC), surgery, and radiotherapy. The
standard of care for NAC includes a taxane, an anthracycline, and/or
cyclophosphamide, and administration of NAC has resulted in pathological
complete response (pCR) in 30-40% of patients. However, a majority of TNBC
patients will not reach pCR and instead have residual disease (RD), which is
associated with worse outcomes. Patients with RD are more likely to experience
locoregional or distant recurrence, and they have lower rates of overall survival,
breast cancer-specific survival, disease-free survival, and distant relapse-free
survival. Five-year survival rates for TNBC are 91% for localized disease, 65%
with regional recurrence, and only 11% with distant recurrence. The reductions in
survival with metastasis indicate that patients who have RD after receiving NAC
desperately need novel interventions. AMP-activated protein kinase (AMPK) and
protein kinase B (Akt) are important cellular energy regulators that have been
implicated in cancer therapy and progression. However, further work is needed to
fully establish their roles as therapeutic modalities in TNBC. This study analyzed
whether targeting the AMPK and Akt signaling pathways can enhance TNBC
therapy or reduce TNBC metastasis.
Chemical activation of AMPK suppresses growth of cancer cells, but many
common AMPK activators—such as AICAR or 2-deoxyglucose—have low
sensitivity and require dosing in the millimolar range. This has led to their
unsuccessful translation to the clinic. FND-4b is a novel compound that activates
AMPK at micromolar concentrations in colorectal cancer cells, but its effects in
TNBC are unknown. Treatment of TNBC cells with FND-4b induced AMPK
activation and signaling through its downstream pathways. Phosphorylation of

acetyl CoA carboxylase (ACC)—a direct target of AMPK—was increased,
indicating a decrease in fatty acid synthesis. Furthermore, activation of ribosomal
protein S6 was reduced, which suggests reduced flux through the mTOR
pathway. FND-4b also suppressed proliferation of TNBC in a dose-dependent
manner in the low micromolar range, which is substantially lower than well-known
AMPK activators. Finally, FND-4b increased apoptosis induction in TNBC cells at
micromolar doses. Taken together, these findings indicate that FND-4b reduces
proliferation and induces apoptosis through AMPK activation in TNBC cells at
lower doses than many other AMPK activators.
AMPK inhibition has increased sensitivity of cancer cells to radiotherapy
due to suppression of autophagy. Chemical inhibition of the PI3K signaling
cascade has also potentiated radiation-induced cell death in TNBC cells.
However, the ability of individual AMPK or Akt isoforms to sensitize TNBC cells
to radiotherapy has not been studied. Moreover, while a double-negative
feedback loop exists between AMPK and Akt—a downstream effector of PI3K—
the impact of combined inhibition of AMPK and Akt isoforms on TNBC survival
after radiation is unknown. Immunohistochemical (IHC) staining indicated that
AMPKα1 is expressed in only the cytoplasm of TNBC, while AMPKα2 is found in
both the cytoplasm and the nucleus. AMPKα1 or AMPKα2 knockdown decreased
proliferation and induced G1 cell cycle arrest in TNBC cells but did not induce
apoptosis alone or in combination with radiotherapy. The role of PI3K p85α,
p85β, p110α, p110β, Akt1, and Akt2 proteins on TNBC cell cycle progression
and apoptosis induction was then analyzed. Akt1 and p110α suppressed cyclin
D1 expression and induced apoptosis. Silencing Akt1 potentiated radiationinduced apoptosis and further suppressed survival of TNBC cells after radiation
exposure. Treatment of TNBC cells with the Akt inhibitor MK-2206 48 h after
radiotherapy decreased Akt1 expression and promoted synergistic apoptosis
induction. Taken together, these results indicate that inhibiting Akt1 expression is
a potentially promising approach to enhance TNBC treatment.
Distant spread of TNBC is correlated with a substantial drop in 5-year
survival. However, the ability of Akt isoforms to mediate TNBC metastasis is
unknown, and the specific steps of metastasis that are regulated by AMPKα
isoforms are unclear. In addition, combined inhibition of Akt and AMPKα isoforms
to suppress TNBC metastatic spread has not been attempted. IHC staining
indicated that Akt1, Akt2, and AMPKα1 were primarily expressed in the
cytoplasm of TNBC lymph node metastases. IHC staining also showed that
AMPKα2 was mostly expressed in both the cytoplasm and nucleus of TNBC
lymph node metastases. Silencing Akt2 reduced expression of the invasive
proteins Snail and Claudin-1 in TNBC cells. Moreover, knockdown of Akt1 and
Akt2 induced apoptosis in TNBC cells potentially by increasing Bim expression
and reducing Mcl-1 expression, respectively. Silencing AMPKα1 or AMPKα2 did
not consistently affect the expression of the invasive proteins tested or induce
apoptosis in TNBC cells. Suppressing levels of Akt1 or Akt2 significantly reduced
TNBC lung colonization independent of Akt activity, but knocking down AMPKα1,

AMPKα2, or AMPKα1/2 did not impact the ability of TNBC cells to metastasize to
the lungs. Moreover, targeting Akt1 and AMPKα1 together did not decrease
TNBC lung metastasis more than silencing Akt1 alone. Taken together, these
results establish Akt1 and Akt2 as key mediators of TNBC metastasis that may
be targeted to prevent the spread of non-responsive disease.
Developing novel therapeutic strategies for TNBC patients who have RD
after administration of NAC is vital to increasing patient survival. Improving
current treatment regimens and reducing metastatic spread are two potential
approaches that may prove advantageous. Pharmacological activation of AMPK
with FND-4b suppressed TNBC growth, and future work could evaluate how
adding AMPK activators to current NAC regimens impacts patient outcomes.
AMPKα1 knockdown did not induce radiosensitization, but silencing Akt1 did
potentiate radiation-induced apoptosis. Moreover, MK-2206 treatment reduced
Akt1 expression and promoted synergistic apoptosis induction after radiotherapy.
Further studies should determine how Akt1 suppression affects outcomes of
TNBC patients with RD after receiving NAC. Finally, silencing Akt1 or Akt2
dramatically decreased TNBC lung metastasis. Knockdown of AMPKα isoforms
did not reduce TNBC lung colonization, and combined inhibition of Akt1 and
AMPKα1 did not suppress TNBC metastasis more than targeting Akt1 alone.
Future studies should identify pharmacological agents that can decrease
expression of Akt1 and Akt2 and evaluate their ability to reduce metastasis.
Taken together, these studies provide potentially promising strategies to improve
survival among TNBC patients whose tumors are refractory to current treatment
modalities.
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CHAPTER 1. INTRODUCTION TO TRIPLE NEGATIVE BREAST CANCER,
AMP-ACTIVATED PROTEIN KINASE, AND PROTEIN KINASE B
1.1 Triple Negative Breast Cancer is Heterogenous
Breast cancer is the most common cancer in women and the second
leading cause of cancer death among women worldwide. Estimates indicate that
there will be more than 275,000 new cases and over 42,000 deaths among US
women in 2020 [1]. Most deaths are due to metastatic spread to the lungs, brain,
or bone [2]. Breast cancer is a heterogeneous disease that can be separated into
three main types: (1) estrogen receptor-positive, (2) receptor tyrosine-protein
kinase erbB-2 (HER2)-amplified, and (3) triple negative. Triple negative breast
cancer (TNBC) comprises 15-20% of overall cases and is characterized by a lack
of expression of the estrogen receptor, the progesterone receptor, and the HER2
protein [3-7]. TNBC affects a younger patient population and has a higher
incidence in African American women [3-5, 7-9]. It follows an aggressive clinical
course and is associated with an increased frequency of metastatic disease [3-5].
Furthermore, patients with TNBC have worse prognoses than patients with other
breast cancers [3, 4, 6, 10].
TNBC is a diagnosis of exclusion and, as such, comprises a heterogenous
group of tumors. The most common subtype is basal-like, which describes
tumors that express proteins found in the basal, or myoepithelial, cell layer of the
breast [4, 11]. These include cytokeratins 5, 6, and 17 and the epidermal growth
factor receptor [4]. Approximately 70% of basal-like breast cancers are classified
as TNBC, while 50-75% of TNBC cases are classified as basal-like [4, 11, 12].
While basal-like is the most common TNBC subtype, several other classifications
exist. Recent gene expression analysis separated TNBC into the following
categories: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M),
mesenchymal stem cell-like (MSL), immunomodulatory (IM), and luminal
androgen receptor-like (LAR) [3-5, 7-9, 13-16]. However, further histological
analysis found that stromal cells or lymphocytes present in the tumors had
influenced the classification of both the MSL and IM subtypes [11, 13, 14, 17].
Therefore, TNBC is now separated into BL1, BL2, M, and LAR [11, 13, 17]. The
BL1, BL2, and M subtypes are nonluminal tumors, while LAR tumors are
classified as luminal [11]. The BL1 subtype has high expression of genes
involved in the DNA-damage response and control of cell cycle, while the BL2
subtype is characterized by increased growth factor signaling and metabolic
activity [11, 13, 18]. Both BL1 and BL2 have a high proliferative capacity and
respond to inhibitors of mitosis, such as taxanes [11]. The M subtype contains
high expression of genes involved in the epithelial-to-mesenchymal transition and
genetic abnormalities in cell motility and differentiation [4, 5, 11, 18]. The LAR
subtype expresses the androgen receptor (AR) and proteins found in luminal
breast cancers [4, 5, 11, 16, 18, 19]. Figure 1.1 compares the frequency of the
BL1, BL2, M, and LAR subtypes in TNBC. Further insight into TNBC
1

heterogeneity may permit the development of targeted therapies for certain
subtypes.
1.2 TNBC Treatment Strategies
TNBC is more difficult to treat than estrogen receptor-positive or HER2amplified breast cancers. The development of targeted therapies—such as
tamoxifen and trastuzumab—has improved the treatment of these other subtypes
[20-23]. Tamoxifen is a selective estrogen receptor modulator and is used to treat
tumors that grow when stimulated by estrogen [20, 21]. Trastuzumab is a
monoclonal antibody that targets the HER2 protein, an oncogene that promotes
cellular growth [22, 23]. By antagonizing this effect, trastuzumab has improved
outcomes of patients whose tumors have high levels of HER2 [22, 23]. However,
TNBC does not contain such targetable factors and has been refractory to
targeted therapies.
Efforts have been made to discover targeted therapy options in TNBC by
focusing on p53, phosphatidylinositol-3-kinase (PI3K) signaling, BRCA1/2, and
the AR. Mutations in the p53 gene are the most common in TNBC and comprise
60-70% of genetic alterations [24-26]. Two compounds that can reactivate p53
function in mutant cells—PRIMA-1 and APR-246—inhibited growth in TNBC cell
lines [27, 28]. TNBC cells with p53 mutations were more sensitive to APR-246
than TNBC cells with wild type p53, but further validation in vivo is still needed
[27]. Activation of the PI3K signaling pathway is also common in TNBC, and
phase I/II clinical trials are evaluating the use of PI3K/mTOR inhibitors in patients
with early or advanced TNBC [9, 29]. The efficacies of two such drugs—
buparlisib and everolimus—have been evaluated in TNBC patients [9]. While the
responses have been modest, there appears to be benefit in targeting this
pathway in TNBC [9]. However, additional studies are needed to clearly delineate
the effects of PI3K pathway inhibitors on patient survival. Germline mutations in
the BRCA1/2 genes are found in 15-20% of TNBC patients and impair the ability
for cells to fix double-stranded DNA breaks [8, 30, 31]. This deficiency in DNA
repair has led to testing PARP inhibitors as part of TNBC therapy [5, 8, 9, 24].
Results so far have been mixed, but third generation derivatives—including
veliparib and olaparib—are currently under investigation [9]. Finally, between 2535% of TNBC tumors express the AR, and clinical trials have indicated that
treatment with two antiandrogens—bicalutamide and enzalutamide—have
provided benefit in AR-expressing TNBC tumors [9]. However, more studies are
needed to determine the minimum AR expression level for these drugs to be
efficacious [9]. Targeting the AR is a promising therapeutic option, but
improvements will only be realized in a subset of TNBC patients whose tumors
depend on the AR to promote signaling and growth.
Currently, the cornerstone of TNBC treatment is cytotoxic chemotherapy
[3, 24]. TNBC tumors are more likely to respond to chemotherapy than other
breast cancers, making this modality an attractive option [24]. Neoadjuvant
2

chemotherapy (NAC) refers to treatment that is administered before surgery and
is becoming more prevalent among TNBC patients. The goal is to shrink the
tumor as much as possible prior to surgery. The standard of care consists of an
anthracycline, a taxane, and possibly a DNA alkylating agent such as
cyclophosphamide [3, 4, 9, 17, 24]. Recently the addition of platinum-based
compounds to the standard treatment regimen has received interest [9].
Platinum-induced DNA damage can lead to apoptosis in cells with a defective
DNA damage response—particularly those with BRCA1/2 mutations [4, 24].
Sixty-one percent of stage I-III TNBC patients with BRCA1 mutations achieved
pathological complete response (pCR) after neoadjuvant therapy with cisplatin
[24]. Moreover, adding carboplatin to standard NAC significantly increased the
rate of pCR in two separate TNBC populations [9, 24].
Localized therapies are also employed in the treatment of TNBC. After
NAC, patients often receive surgery, radiotherapy, and possibly adjuvant
chemotherapy [32-35]. The standard protocol for breast cancer is administration
of 50.0 Grays (Gy) of radiation [36]. Delivery occurs in 25 sessions over 5 weeks,
which results in 2.0 Gy being given each day [36]. There are no specific
guidelines for radiotherapy in TNBC [8]. Recent studies have shown that
radiation can improve TNBC patient outcomes. Radiation treatment increased
both breast cancer-specific survival (BCSS) and overall survival (OS) among
TNBC patients after surgery [33, 34]. The effect on BCSS was slight for patients
in the T1-T2 population but much greater for those in the T3-T4 populations,
suggesting that radiation benefits are greater in patients with more advanced
tumors [34]. Radiotherapy also increased BCSS among patients who had a
partial mastectomy but not a total mastectomy, which indicates that the type of
surgery a patient receives may also impact the efficacy of radiotherapy [34].
BCSS still declines over time in patients who receive radiation, which suggests
that there is still room for improvement [34].
1.3 Treatment Efficacy and Achieving pCR
Improvements in TNBC treatment have been made, but there is still much
work left to do. TNBC patients have a higher rate of recurrence and worse
survival than patients with other types of breast cancer [5, 11]. Distant relapsefree survival (DFRS) is significantly shorter among patients with TNBC than
among those with non-TNBC [13]. In addition, TNBC survival decreases
considerably with regional and distant metastasis. The 5-year relative survival
rate for localized TNBC is 91% [37]. This rate drops to 65% for those with
regional disease and plummets to 11% in cases with distant spread [37]. These
substantial reductions in survival with metastasis underscore the importance of
early detection and the need for effective treatments at early stages of disease.
TNBC patient outcome is directly impacted by the attainment of pCR,
which is the absence of cancer on pathological examination of the resected
breast and all sampled lymph nodes after NAC [38]. While patients who achieve
3

pCR have better outcomes than those who do not, administration of NAC has led
to pCR in only 30-40% of TNBC patients [24, 39-41]. This means that 60-70% of
TNBC patients do not reach pCR and instead have residual disease (RD) at the
time of surgical resection. Moreover, TNBC subtype impacts pCR achievement
and subsequent clinical outcome. Compared to other TNBC patients, those with
the BL2 subtype reach pCR at the lowest rate and have the worst median
survival [13, 42]. One study has found that BL2 patients have a median survival
of just 2.4 years, which is the shortest among the major TNBC subtypes [13].
TNBC patients who do not achieve pCR despite treatment with NAC
desperately need novel interventions for two key reasons. First, those with RD
are more likely to experience locoregional or distant recurrence than those who
do achieve pCR [8, 43]. Patients with RD are more likely to die from distant
spread of their cancers than those who reach pCR [13]. A recent study showed
that TNBC patients with RD after NAC developed locoregional recurrence at a
disproportionately higher rate than those with other breast cancers [32]. These
patients also received surgery and radiation, which suggests that recurrent
tumors may be resistant to localized therapies [32]. Second, disease-free
survival, DRFS, BCSS, and OS are significantly lower in TNBC patients with RD
than in those with pCR [13, 39-41]. A recent analysis found that 95% of TNBC
patients with pCR were alive after 7 years while those without pCR had a median
survival of only 2.7 years [13].
Patients with stage II or III TNBC could benefit from increasing the rate of
pCR. Stage II disease can be classified by a tumor that is larger than 20 mm or
the presence of 1-3 positive lymph nodes [35]. Stage III disease can be classified
by a tumor that is larger than 50 mm or the presence of 4-9 positive lymph nodes
[35]. Figure 1.2 outlines a standard treatment protocol for these patients, which
includes NAC that is followed by surgery [35]. Those patients who reach pCR
usually receive radiotherapy and are then monitored [35]. Patients who still have
RD normally receive radiotherapy that is followed by adjuvant chemotherapy [35].
Capecitabine is normally administered for these patients in the adjuvant setting
[35].
TNBC patients who are refractory to standard treatments—notably those
with the BL2 subtype—are in dire need of novel therapeutic strategies. Two
potential options include improving the efficacy of NAC by identifying new drug
targets or increasing the sensitivity of cancer cells to radiotherapy. The enzymes
AMP-activated protein kinase (AMPK) and protein kinase B (Akt) have been
implicated in cancer therapy and progression. However, further work is needed to
fully define their roles as therapeutic targets in TNBC.
1.4 AMPK Structure and Regulation
AMPK is a heterotrimer that consists of a catalytic (α) and two regulatory
(β and γ) subunits [44-57]. Each subunit is further composed of different isoforms
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[44-47, 50-54, 56]. The α subunit is activated via phosphorylation of Threonine
(Thr) 172 and is responsible for phosphorylating downstream targets [44, 45, 47,
48, 50-52, 54-57]. It contains a kinase domain (KD), an auto-inhibitory domain
(AID), and a C-terminal domain (CTD) [47, 48]. The KD is composed of large and
small lobes, and Thr172 is located in the large lobe [47, 48]. When associated
with the AID, the activity of the KD is greatly reduced [47, 48]. The AID must be
moved away from the KD to increase activation. In the active confirmation, the
CTD protects Thr172 from dephosphorylation by phosphatases [47].
The β subunit contains a carbohydrate-binding module (CBM) and a Cterminal domain (CTD) [47, 48]. The β-CTD links the α-CTD with the γ subunit,
while the CBM is able to bind glycogen [47, 48]. The purpose of AMPK binding to
glycogen is not fully understood yet [47, 48]. The γ subunit is comprised of four
cystathione β-synthase (CBS) repeats whose main role is to detect changes in
cellular AMP levels [47, 48, 53]. CBS1, CBS3, and CBS4 can bind to adenosinecontaining nucleotides, while CBS2 is nonfunctional and unable to do so [47, 48].
CBS1 is mostly bound to ATP, while CBS4 binds AMP with high affinity [58].
CBS3 is the only structure that has an interaction with the α subunit [58].
Furthermore, CBS3 can competitively bind to AMP, ADP, or ATP and is therefore
the main sensor of variations in cellular energy [48, 53]. Binding of AMP or ADP
to CBS3 causes the γ subunit to interact with the α subunit, which results in a
conformational change that moves the AID away from the KD [53]. This relieves
the inhibitory effects of the AID on the KD and ultimately leads to allosteric
activation of AMPK [53].
AMPK is phosphorylated at Thr172 by three upstream enzymes: liver
kinase B1 (LKB1), calcium/calmodulin dependent protein kinase kinase 2
(CAMKK2), and transforming growth factor-β activated protein kinase-1 (TAK1)
[44, 45, 47, 48, 50-52, 54-56]. LKB1 is a tumor suppressor that is mutated in
Peutz-Jeghers Syndrome, a disorder in which hamartomatous polyps grow in the
gastrointestinal tract [47, 49, 50, 55]. LKB1 exerts its anti-tumor effects by
signaling through AMPK and twelve other related enzymes [45, 48, 55]. CAMKK2
activates AMPK in response to increases in intracellular Ca 2+ levels and works
independently of changes in cellular AMP levels [47, 50, 52, 56]. This mechanism
permits AMPK activation even when cells are not metabolically stressed.
Phosphorylation of AMPK by CAMMK2 occurs in depolarized neurons in the
hippocampus, activated T cells, and cells in which a G protein-coupled receptor
has been stimulated to release Ca2+ intracellularly [47]. TAK1 can induce AMPK
activation, but little is known about the physiological purpose of this signaling [48,
56].
Changes in AMP levels are key for cells to detect and respond to energy
stress. ATP, ADP, and AMP are related through the following reaction: 2 ADP ⇌
ATP + AMP [47, 48]. ATP levels are reduced during metabolic stress, causing
the reaction to favor the production of ATP and AMP [47, 48]. Since initial AMP
levels are much lower than initial ATP levels, changes in the AMP concentration
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will be greater than changes in the concentration of either ATP or ADP [47].
Therefore, AMP levels are acute markers of metabolic stress [47]. An increase in
AMP signifies metabolic demand and promotes AMPK activation three ways.
First, AMP binds the γ subunit of AMPK, leading to a conformational change that
breaks the association between the KD and the AID in the α subunit [47, 53].
This results in allosteric activation of AMPK [47, 53]. Next, AMP stimulates LKB1induced phosphorylation of Thr172 [47]. Finally, the conformational change from
AMP binding to AMPK’s γ subunit prevents protein phosphatases from
dephosphorylating Thr172 [47, 53]. ADP can also suppress this
dephosphorylation, but the required concentration is 10 times higher than that for
AMP [47].
1.5 AMPK Function
1.5.1 Effects on Metabolism
AMPK is activated when cellular AMP levels rise, which occurs when the
cell is in a low energy state [47, 52]. AMPK attempts to return the cell to energy
homeostasis by increasing ATP production and reducing ATP consumption [47,
52]. This is accomplished through upregulation of catabolic pathways—those that
produce ATP—and downregulation of anabolic pathways—those that consume
ATP [47, 52, 53]. AMPK’s effects on cellular metabolism are wide-ranging and
described in more detail below.
AMPK suppresses synthesis of fatty acids, cholesterol, and proteins.
Acetyl-CoA carboxylase (ACC) is the rate-limiting enzyme in fatty acid synthesis
and is directly regulated by AMPK [47-50, 52-56]. When phosphorylated, ACC is
inactivated and therefore unable to catalyze the formation of malonyl-CoA, a
compound involved in fatty acid synthesis [47, 53, 56]. AMPK also regulates
cholesterol synthesis by phosphorylating and inhibiting 3-hydroxy-3methylglutaryl-CoA reductase (HMGCR) [47-50, 52, 54-56]. Finally, AMPK
suppresses protein synthesis by decreasing flux through the mammalian target of
rapamycin 1 (mTORC1) by activating the tuberous sclerosis complex 2 (TSC2)
and inhibiting raptor [47-50, 53-56]. Inactivation of mTORC1 suppresses both the
initiation and elongation steps in protein translation [56].
AMPK upregulates ATP production through fatty acid oxidation and
glycolysis. AMPK-induced downregulation of malonyl-CoA leads to stimulation of
carnitine palmitoyltransferase 1 (CPT1), an enzyme that facilitates transportation
of fatty acids from the cytoplasm into the mitochondrial matrix where they are
oxidized to produce energy [47, 48, 51-53, 56]. In addition, AMPK upregulates
mitochondrial biogenesis [47, 56]. AMPK promotes fusion of the glucose
transporter type 4 (GLUT-4) with the cell membrane, leading to an increase in
intracellular glucose levels [47, 48, 52, 53, 56]. AMPK also stimulates glycolysis
by activating phosphofructokinase-2, an enzyme that leads to the production of
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fructose-2,6-bisphosphate [48, 53, 56]. Phosphofructokinase-1 is a glycolytic
enzyme that is allosterically activated by fructose-2,6-bisphosphate [48, 56].
1.5.2 Effect on Autophagy
AMPK is also able to regulate the induction of autophagy, which is a
process by which cells consume damaged or unneeded organelles for energy to
promote survival [45]. When cells are energy-starved or experience stress,
AMPK initiates autophagy by phosphorylating and activating the enzyme Unc-51
like autophagy activating kinase 1 (ULK1) [45]. AMPK also stimulates autophagy
by decreasing flux through mTOR, a negative mediator of ULK1 [53]. Finally,
AMPK promotes autophagy by regulating structures that contain vacuolar protein
sorting 34 (VPS34), which are involved with autophagosome formation [53]. By
promoting autophagy, AMPK prevents cells from undergoing apoptosis and
thereby provides a direct survival advantage.
1.6 AMPK in TNBC
While AMPK is known to regulate metabolism in normal tissue, it is also
associated with disease progression, cellular proliferation, and metabolism in
TNBC. AMPK expression was higher in TNBC compared to other breast cancer
subtypes or normal cells [59, 60]. Moreover, AMPK expression was increased in
breast cancers larger than 2 centimeters or breast tumors with advanced stage
[61]. Furthermore, increased AMPK expression was associated with lower OS
and DFS in TNBC [60]. Upregulation of AMPK in TNBC cells increased glucose
uptake, glycolytic flux, proliferation in vitro, and tumor growth in vivo [60].
Silencing of AMPK in TNBC cells led to similar results—decreased flux through
glycolysis and a reduction in in vivo tumor growth [62]. Taken together, these
findings indicate that AMPK promotes TNBC growth by stimulating ATP
production through glycolysis. However, distinctions have not been made
between the α1 and α2 isoforms in TNBC. AMPKα2 has previously been shown
to suppress estrogen receptor-positive breast cancer growth by inducing G1 cell
cycle arrest and promoting apoptosis [63]. Furthermore, AMPKα2 reduces growth
of bladder cancer and hepatocellular carcinoma through p27 and p53,
respectively [64, 65]. It is possible that the α2 isoform has a similar function in
TNBC, but further work is needed to establish the roles of each individual
isoform.
1.6.1 AMPK as a Chemotherapeutic Target
Small molecules can activate AMPK to levels that are much higher than
what normally occurs in a cell or tissue. When this happens, AMPK starts
suppressing cellular growth. At such an elevated level, AMPK can prevent
anabolism, reduce cellular proliferation, decrease flux through the mTOR
pathway, and induce apoptotic cell death [66-75]. However, the most well-known
AMPK activators—including AICAR and 2-deoxyglucose—lack sensitivity and
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require dosing in the millimolar range [76]. Such high concentrations result in
side effects that are difficult for patients to tolerate and have prevented these
compounds from being translated to the clinic. In addition, many common AMPK
activators have wide-ranging cellular effects and reduce proliferation in AMPKknockdown cells, indicating that these compounds target multiple pathways [76].
This lack of specificity is another drawback to the usefulness of AMPK activators
in cancer patients. While AMPK activation is a promising therapeutic strategy for
TNBC, there is a need to develop novel compounds with increased sensitivity
and specificity. Recent efforts have focused on this goal, and compounds such
as OSU-53 and RL-71 activate AMPK and reduce proliferation in the micromolar
range [67, 72]. Other studies have found that FDA-approved drugs—such as
fluoxetine, tamoxifen, or metformin—can activate AMPK and may provide benefit
in TNBC therapy [70, 71, 73-75]. While some progress has been made, there is
still room for improvement. Future work should involve identifying novel
compounds that activate AMPK at lower concentrations and with fewer side
effects.
1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4(trifluoromethoxy)phenyl)urea (FND-4b) is a novel compound synthesized at the
University of Kentucky that can activate AMPK at low micromolar doses, making
it substantially more sensitive than AICAR, 2-deoxyglucose, or metformin [77,
78]. As a result, FND-4b may possess a much more favorable side effect profile
than other AMPK activators. FND-4b has previously been shown to suppress
proliferation of colorectal cancer cells, but its effects have not been tested in
TNBC [77].
1.6.2 AMPK as a Radiosensitizer
AMPK also plays an important role in mediating the cellular response to
radiotherapy. Radiation exposure induced activation of AMPK in lung, prostate,
breast, and colorectal cancer cells and also increased total AMPK levels in lung
cancer cells [45, 79-81]. Levels of phosphorylated AMPK were increased in both
the nucleus and cytoplasm in lung cancer cells after irradiation [79]. However,
AMPK’s impact on cell survival after radiotherapy is complex and varies among
tumor types. In certain cancers, AMPK activation potentiates radiation damage.
Activation of AMPK with metformin led to mTOR inhibition and increased
sensitivity to radiation in estrogen receptor-positive breast cancer cells [82]. In
esophageal cancer, metformin also induced cell cycle arrest, reduced mTOR
signaling, and enhanced radiation-induced decreases in survival [83].
Administration of metformin also further reduced survival of lung cancer cells
after radiation exposure [79].
Inhibition of AMPK sensitized other cancers to the effects of radiotherapy.
AMPK mediated the autophagy induction in response to radiation in esophageal
and nasopharyngeal cancers [84, 85]. Furthermore, AMPK inhibition with
compound C sensitized these cells to the effects of radiation [84, 85]. In
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radiation-resistant colorectal cancer, expression of phosphorylated and total
AMPK were upregulated [86]. Silencing or inhibiting AMPK overcame this
resistance and potentiated radiation-induced death [86]. However, the impact of
AMPK signaling on TNBC survival after radiation exposure is unknown and
needs further study.
Inhibiting AMPK function may sensitize TNBC cells to radiation through
two mechanisms. First, knockdown of AMPK could limit ATP production in TNBC
cells. Rates of catabolic processes—such as glycolysis or fatty acid oxidation—
may decline, while rates of anabolic processes—such as fatty acid synthesis—
may increase. This could lead to an imbalance of the cellular ATP/AMP ratio.
Radiation induces aerobic glycolysis, and limiting energy mobilization through
glycolysis may prevent cells from mounting an adequate survival response [87].
Moreover, DNA repair is an energy-intensive process and may be ineffective
without sufficient resources. If damaged DNA is not fixed, then cells will undergo
apoptosis. In addition, AMPK inhibition could suppress autophagy induction in
TNBC cells that have been exposed to radiation. With the autophagy pathway
diminished, damaged cells will be less likely to survive the stress conditions from
radiotherapy. This could also lead to an increase in apoptosis induction.
1.6.3 Effect of AMPK on Metastasis
AMPK’s ability to mobilize energy may help cells metastasize to distant
organs. In particular, cells that have detached from a matrix cannot import
glucose from their environment and must instead generate ATP from other
pathways [88]. Moreover, fatty acid oxidation and lipid synthesis—both of which
are regulated by AMPK—can promote metastasis [89]. AMPK isoforms affect
TNBC metastasis in an isoform-dependent manner [90, 91]. AMPKα1 has been
shown to suppress distant spread of TNBC, while AMPKα2 promotes TNBC
metastasis [90, 91]. However, the specific steps in the metastatic process that
are regulated by AMPKα isoforms are unclear.
1.7 Akt Signaling and Function
Akt is a downstream effector of phosphatidylinositol-3 kinase (PI3K) that
can control signaling through the mTOR pathway and is composed of three
isoforms: Akt1, Akt2, and Akt3 [92, 93]. Akt1 is widely expressed in the body and
can be mutated or amplified in cancers [92, 93]. Akt2 has a more limited
distribution and has high expression in adipocytes and muscles [92]. However,
Akt2 is more frequently amplified in cancers than Akt1 [92]. Akt3 has a very
limited distribution with the most expression in the brain and the testes [92, 94].
All three isoforms have a similar structure: a pleckstrin homology domain, a
helical region, a kinase domain, and a regulatory motif [92]. However, they differ
slightly in the location of the phosphorylation residues in the kinase and
regulatory domains [92]. Akt1 is activated by phosphorylation of Thr308 in the
kinase domain; in Akt2 and Akt3, this residue is Thr309 and Thr305, respectively
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[92, 94]. Akt1 activation is also promoted by phosphorylation of Serine 473
(Ser473) in the regulatory motif; in Akt2 and Akt3, this residue is Ser474 and
Ser472, respectively [92, 95].
Akt has wide-ranging effects in the body and impacts metabolism, protein
translation, proliferation, survival, and angiogenesis through a variety of
downstream effectors [92]. For instance, Akt impacts protein translation by
regulating mTOR and TSC2, and it controls metabolism through effects on insulin
receptor substrate 1 (IRS1) and glycogen synthase kinase 3 (GSK3) [92]. Akt
also influences proliferation through effects on cyclin-dependent kinase inhibitor
1 and cyclin-dependent kinase inhibitor 1B [92]. Moreover, Akt impacts cellular
survival by regulating Forkhead box protein O1 (FOXO1), pro-caspase 9, and
BAD [92]. Finally, Akt affects angiogenesis through nitric oxide synthase 3
(NOS3) [92]. As a result of this extensive signaling, Akt plays a role in diabetes,
cardiovascular disease, and neoplasia [92].
1.8 Akt in TNBC
The PI3K signaling pathway is the most frequently altered pathway in
breast cancer [96]. Alterations are also common in TNBC and are found in 29.8%
of cases [97]. In particular, activating mutations in the PI3K catalytic subunit α
(p110α) are the most frequent in breast cancer [96]. Mutations in p110α are
present in 23.7% of TNBC cases [96]. This suggests that signaling through Akt
may be upregulated in a substantial number of TNBC tumors. Consequently,
there may be clinical benefit in targeting Akt signaling to enhance current therapy
or reduce metastatic spread.
1.8.1 Akt as a Radiosensitizer
The capacity of Akt to promote cellular survival could indicate that it plays
an important role in the cellular response to radiation-induced stress. The
PI3K/Akt/mTOR signaling pathway has been targeted pharmacologically to
enhance the efficacy of radiotherapy in estrogen receptor-positive and TNBC
cells [98-102]. Moreover, ectopic expression of Akt1 has been shown to promote
radiation resistance in estrogen receptor-positive breast cancer cells [103].
However, specific Akt isoforms have not been targeted to induce
radiosensitization in TNBC. Moreover, combined suppression of AMPKα and Akt
isoforms to enhance radiotherapy in TNBC cells has not been attempted.
1.8.2 Effect of Akt on Metastasis
Akt’s ability to regulate cellular metabolism and survival suggests that it
may have a prominent role in controlling metastatic spread of TNBC tumors.
Prior studies have analyzed the role of Akt isoforms in breast cancer metastasis.
Akt1 has been shown to suppress metastasis in estrogen receptor-positive and
HER2-amplified breast cancers [104-106]. Conversely, Akt2 promotes metastasis
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of both estrogen receptor-positive and HER2-amplified breast cancers [105, 106].
However, the effect of Akt isoforms on TNBC metastasis is unknown. In addition,
combined inhibition of AMPKα and Akt isoforms to reduce TNBC metastasis has
not previously been attempted.
1.9 Hypothesis
This project was undertaken with the goal of understanding whether
AMPK and Akt can be targeted to improve TNBC therapy and reduce TNBC
metastasis. The hypothesis is that: (1) AMPK activation with the novel compound
FND-4b will reduce proliferation of TNBC cells, (2) silencing AMPKα and Akt
isoforms will enhance radiation-induced apoptosis in TNBC cells, and (3)
suppression of AMPKα and Akt isoforms will reduce TNBC metastasis.

11

Figure 1.1 TNBC is primarily composed of four subtypes.
TNBC is a heterogeneous disease that can be separated into four main
subtypes. The basal-like 1 (BL1) subtype is the most common and comprises
35% of cases. The mesenchymal (M) subtype is the next most common and
makes up 25% of cases. The basal-like 2 (BL2) subtype is the third most
common and comprises 22% of cases. The luminal androgen receptor (LAR)
subtype is the least common and makes up 16% of cases. A small minority of
cases (2%) do not fit into any of the four main categories and are considered
unclassified. Data to prepare this graph were obtained from [13].
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Figure 1.2 Treatment protocol for stage II and III TNBC patients.
Patients with stage II or III TNBC often receive NAC consisting of an
anthracycline, a taxane, and/or a cyclophosphamide prior to surgery. Patients will
then receive either a lumpectomy or a mastectomy. At the time of surgery, a
pathologist determines whether a patient has achieved pCR or still has RD.
Those who reach pCR usually receive radiation therapy and are then monitored.
Patients who still have RD normally receive radiation therapy followed by
adjuvant chemotherapy (capecitabine). Those patients who have RD after
receiving NAC have an increased risk of recurrence and decreased survival.
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CHAPTER 2. INDUCTION OF AMPK ACTIVATION BY N,N’-DIARYLUREA
FND-4B DECREASES GROWTH AND INCREASES APOPTOSIS IN TRIPLE
NEGATIVE AND ESTROGEN-RECEPTOR POSITIVE BREAST CANCERS
2.1 Abstract
Purpose: Triple negative breast cancer (TNBC) is the most lethal and
aggressive subtype of breast cancer. AMP-activated protein kinase (AMPK) is a
major energy regulator that suppresses tumor growth, and 1-(3-chloro-4((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a
novel AMPK activator that inhibits growth and induces apoptosis in colon cancer.
The purpose of this project was to test the effects of FND-4b on AMPK activation,
proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC.
Materials and methods: (i) Estrogen-receptor positive breast cancer
(ER+BC; MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast
cancer stem cells were treated with FND-4b for 24h. Immunoblot analysis
assessed AMPK, acetyl-CoA carboxylase (ACC), ribosomal protein S6, cyclin
D1, and cleaved PARP. (ii) Sulforhodamine B growth assays were performed
after treating ER+BC and TNBC cells with FND-4b for 72h. Proliferation was also
assessed by counting cells after 72h of FND-4b treatment. (iii) Cell death ELISA
assays were performed after treating ER+BC and TNBC cells with FND-4b for
72h.
Results: (i) FND-4b increased AMPK activation with concomitant
decreases in ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii)
FND-4b decreased proliferation in all cells, while dose-dependent growth
decreases were found in ER+BC and TNBC. (iii) Increases in apoptosis were
observed in ER+BC and the MDA-MB-231 cell line with FND-4b treatment.
Conclusions: Our findings indicate that FND-4b decreases proliferation
for a variety of breast cancers by activating AMPK and has notable effects on
TNBC. The growth reductions were mediated through decreases in fatty acid
synthesis (ACC), mTOR signaling (S6), and cell cycle flux (cyclin D1). ER+BC
cells were more susceptible to FND-4b-induced apoptosis, but MDA-MB-231
cells still underwent apoptosis with higher dose treatment. Further development
of FND compounds could result in a novel therapeutic for TNBC.
2.2 Introduction
Breast cancer is the most common cancer in women and the main cause
of cancer-related death among women worldwide. In 2018 alone, there will be
more than 266,000 newly diagnosed cases of breast cancer in women in the
United States and almost 41,000 deaths [107]. Up to 30% of patients develop
metastases, and 90% of deaths result from metastases to the lung, brain, or
bone [2]. Breast cancer is a heterogeneous disease separable into three main
types: estrogen-receptor positive breast cancer (ER+BC), HER2-amplified breast
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cancer, and triple negative breast cancer (TNBC). Although TNBC comprises
only 15-20% of total cases, it is the most lethal and aggressive of the three types
[3, 4].
The principal characteristics of TNBC include: (1) reduced expression of
the estrogen and progesterone receptors and (2) no overexpression of HER2.
TNBC affects a younger patient population than the population afflicted with other
types of breast cancer and leads to an increased risk of recurrence and
metastases [3]. Not surprisingly, patients with recurrent TNBC have a worse
prognosis than that for patients with recurrent forms of other breast cancers [3].
In addition, patients with TNBC have limited therapeutic options because their
tumors lack the traditional steroid hormone receptors and HER2 amplification.
Instead, patients usually receive a drug cocktail that includes an anthracycline
antineoplastic agent, a DNA alkylating agent, and a taxane [3]. These
chemotherapeutic agents are toxic to normal and cancer cells alike and result in
serious side-effects that are difficult for patients to tolerate. Recent efforts have
focused on developing therapies that specifically target cancer cells without
affecting normal cells. Because oncogenic transformation requires major
metabolic reprogramming to produce energy, redox cofactors, and molecules
involved in DNA modification, new agents that target the increased metabolism
within cancer tissue more than the metabolism in normal tissue are attractive
therapeutic options [2].
AMP-activated protein kinase (AMPK) is a cellular energy sensor that has
important implications in cancer progression [44, 45, 47-52, 54-57]. When
activated by ATP depletion, the phosphorylated form of AMPK causes the
following changes in TNBC: (1) inhibition of anabolic and oncogenic pathways,
(2) attenuated mTOR signaling, (3) decreased cell proliferation, and (4) apoptosis
[66-75]. Well-known AMPK activators, such as 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) and 2-deoxyglucose (2-DG), require high doses to affect
cancer cell proliferation, which has led to their unsuccessful translation to the
clinic for cancer therapy [50]. Among the attempts to produce new AMPK
activators with increased sensitivity, the fluorinated N,N’-diarylureas (FNDs)
serve as activators that lead to phosphorylated AMPK at low concentrations [77,
78]. In particular, 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4(trifluoromethoxy)phenyl)urea (FND-4b) inhibits growth and induces apoptosis in
colorectal cancer cells, but its potential effects on other types of cancer remain
unclear [77]. Because of the pressing need to develop new treatments for TNBC,
we tested the effects of FND-4b on TNBC and compared the results with ER+BC.
Importantly, we found that treatment with FND-4b led to AMPK activation,
decreased cell cycle flux, and increased apoptosis in both subtypes. These
findings indicate that FND compounds may be potential therapeutic options for
TNBC.
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2.3 Materials and methods
2.3.1 Reagents, supplements, and antibodies
1-(3-Chloro-4-((trifluoromethyl)thio)phenyl)-3-(4(trifluoromethoxy)phenyl)urea (FND-4b) was synthesized and characterized as
previously described [78]. Roswell Park Memorial Institute (RPMI) 1640 Medium
and Eagle’s Minimum Essential Medium (EMEM) were purchased from SigmaAldrich (St. Louis, MO). Dulbecco’s Modified Eagle Medium (DMEM) was from
Corning (Corning, NY). Human breast cancer stem cell complete growth medium
was from Celprogen (Torrance, CA). MEM non-essential amino acid solution
(100x), sodium pyruvate solution (100 mM), insulin solution (10 mg/mL),
penicillin-streptomycin (100x) (P/S), and fetal bovine serum (FBS) were from
Sigma-Aldrich. 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) was
from Abcam (Cambridge, MA). Antibodies for pAMPKα (Thr172), total AMPKα,
phosphorylated acetyl-CoA carboxylase (ACC), total ACC, phosphorylated
ribosomal protein S6, total S6, and PARP were from Cell Signaling Technology
(CST; Danvers, MA). The cyclin D1 antibody was from Abcam. The beta-actin
antibody was from Sigma-Aldrich. The secondary antibodies to rabbit and mouse
were from Santa-Cruz. All relevant antibody information is in Table 1 below. The
Sulforhodamine B (SRB) Cytotoxicity Assay was from G-Biosciences (St. Louis,
MO). The Cell Death Detection ELISAPLUS assay was from Sigma-Aldrich.
2.3.2 Cell culture
MCF-7, T-47D, MDA-MB-231, HCC-1143, and HCC-1806 cells were
purchased from ATCC, while breast cancer stem cells were purchased from
Celprogen. MCF-7 cells were maintained in EMEM containing 10% FBS, 1% P/S,
0.01 mg/mL insulin, 1x non-essential amino acids, and 1 mM sodium pyruvate. T47D cells were maintained in RPMI containing 10% FBS, 1% P/S, and 0.2
Units/mL insulin. MDA-MB-231, HCC-1143, and HCC-1806 cells were
maintained in RPMI with 10% FBS and 1% P/S. Breast cancer stem cells were
maintained in breast cancer stem cell medium supplemented with 10% FBS and
1% P/S. All cells were grown in an incubator at 37°C and 5% CO2. For cell
treatments, 7x105 MCF-7 and T-47D cells or 8x105 MDA-MB-231, HCC-1806,
and breast cancer stem cells were seeded in 6-well plates and incubated
overnight. The medium was removed on the following day, and cells were treated
with fresh medium that contained different concentrations of FND-4b (0, 1, 2.5, 5,
10, and 20 µM) for 24 h before lysis.
2.3.3 Western blot analysis
After treatment, cells were scraped from the wells with 1x RIPA buffer
containing serine protease inhibitor. The cells were lysed by incubating on ice for
20 min and vortexing 10 sec every 5 min. The lysates were centrifuged at 14,000
rpm and 4°C for 20 min, and the protein concentration was determined using the
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Bradford method. The proteins were reduced and denatured by heating at 80°C
for 10 min. An equal amount of protein was resolved on SDS-PAGE gels and
transferred to PVDF membranes. The membranes were blocked with 10% milk
before overnight incubation with primary antibodies at 4°C. On the following day,
the membranes were washed with Tris buffered saline with 0.1% tween-20
(TBST) for 5 min and again for 10 min. The membranes were subsequently
incubated with the appropriate secondary antibody for 30 min at room
temperature. The membranes were then washed with TBST for 15 min and again
for 20 min. Proteins were visualized with Amersham ECL (GE Healthcare) or
Immobilon (Millipore). Membranes were stripped and reprobed as necessary.
2.3.4 Cell counting assay
Cells (1x105) were seeded in 6-well plates and incubated overnight. The
medium was removed on the following day, and cells were grown in fresh
medium that contained either: (a) 0 or 5 µM FND-4b or (b) 0 or 1 mM AICAR for
72 h. Cells were then washed with PBS, trypsinized, and counted with a
Beckman-Coulter cell counter.
2.3.5 SRB growth assay
Cells (5x103 in 100 µL) were seeded in 96-well plates and incubated
overnight. On the following day, fresh media was prepared to contain twice the
desired concentrations of FND-4b (i.e., 5, 10, 20, and 40 µM). Then 100 µL of the
new media solutions were added to the wells without removing the old media;
this yielded 200 µL per well and halved the FND-4b concentrations. Cells were
grown in the media with different final concentrations of FND-4b (0, 2.5, 5, 10,
and 20 µM) for 72 h before the proteins were fixed at 4°C for 1 h. The wells were
washed 3 times with water and then dried for 30 min. The SRB dye solution
(0.4%) was added to the wells and incubated for 30 min. The excess dye was
washed off with 1% acetic acid, and the wells were allowed to air dry. The dye
was solubilized with a 10 mM Tris solution, and the absorbance was measured at
565 nm or—if the readings were outside of the instrument’s linear range—at 490
nm.
2.3.6 Cell Death Detection ELISAPLUS assay
Cells (5x103 in 100 µL) were seeded in 96-well plates and incubated
overnight. On the following day, fresh media was prepared to contain twice the
desired concentrations of FND-4b (i.e., 5, 10, and 20 µM). Then 100 µL of the
new media solutions were added to the wells without removing the old media;
this yielded 200 µL per well and halved the FND-4b concentrations. Cells were
cultured in the media with different final concentrations of FND-4b (0, 2.5, 5, and
10 µM) for 72 h. Cells were then centrifuged at 200 x g for 10 min and lysed for
30 min with shaking. The lysates were centrifuged at 200 x g for 10 min, and 20
µL of supernatant was transferred to streptavidin-coated wells. Then 80 µL of the
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immunoreagent (anti-histone biotin and anti-DNA peroxidase) was added to the
streptavidin-coated wells. The plates were shaken for 2 h at room temperature
before the wells were rinsed three times with incubation buffer. Color change was
initiated by adding the substrate ABTS to the wells, and the plates were shaken
until the color change was sufficient for photometric analysis. After adding the
ABTS Stop Solution, absorbance was measured at 405 nm.
2.3.7 Statistical analysis
Comparisons of SRB growth and ELISA assays across non-treated and
different dose groups of FND-4b were performed using analysis of variance
(ANOVA) with test for linear trend across dose levels. Pairwise comparisons of
each FND-4b dose level versus non-treated group were performed within the
ANOVA model with Holm's p-value adjustment for multiple testing. Comparisons
of baseline ELISA values between HCC-1806 cells and other cell lines were
performed using ANOVA with least squares means and adjustment for multiple
comparisons. Comparisons of cell counting assays between control and FND-4bor AICAR-treated groups were performed using two-sample t-tests with
homogeneity of variance assessed for the use of the t-test for two group
comparisons. Analyses were performed on data normalized with the non-treated
group for the SRB growth and cell counting assays and on the raw data for the
ELISA assays. In all experiments, p-values less than 0.05 were considered
significant.
2.4 Results
2.4.1 Analysis of pAMPKα expression in breast cancer subtypes
Prior work has suggested that TNBC cell lines and tissues have higher
levels of phosphorylated and total forms of AMPKα than non-TNBC cells and
tissues [59]. Consequently, we compared levels of pAMPKα and total AMPKα in
TNBC and ER+BC cells using western blotting. We found no difference in levels
of phosphorylated or total AMPKα between two ER+BC cell lines (MCF-7 and T47D) and three TNBC cell lines (MDA-MB-231, HCC-1143, and HCC-1806)
(Figure 2.1).
2.4.2 FND-4b activated AMPKα and downstream signaling pathways in breast
cancer
Because FND-4b activated AMPKα in colon cancer cells, we investigated
its effects in several subtypes of breast cancer [77]. In particular, MCF-7, T-47D,
MDA-MB-231, HCC-1806, and breast cancer stem cells were treated with fresh
medium containing a range of FND-4b concentrations (0, 1, 2.5, 5, 10, and 20
µM) for 24 h. Protein levels of phosphorylated and total forms of AMPKα, acetylCoA carboxylase (ACC), and ribosomal protein S6, cyclin D1, and cleaved PARP
were measured with immunoblotting. ACC and S6 were selected for analysis
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because they are downstream effectors of AMPKα that are phosphorylated and
dephosphorylated, respectively, with AMPKα activation. As expected based on
prior work, FND-4b treatment increased levels of pAMPKα in all five cell lines
(Figure 2.2) [77]. Consistent with this result, increases in pACC and decreases in
pS6 were also noted. Cyclin D1, an AMPKα-regulated marker for flux through the
cell cycle, was decreased in all cell lines treated with FND-4b. Increases in the
apoptotic indicator cleaved PARP were observed in MCF-7, MDA-MB-231, and
HCC-1806 cells with AMPKα activation. FND-4b concentrations less than 5 µM
yielded minimal effects on AMPK signaling, but the 5 µM dose yielded robust
effects in all cells tested. The HCC-1806 cells were notable because AMPKα
activation spiked with 5 µM FND-4b treatment and then declined with
concentrations higher than 5 µM. Taken together, these results indicate that
FND-4b activates AMPKα and its downstream signaling pathways in TNBC,
ER+BC, and breast cancer stem cells.
2.4.3 FND-4b decreased growth of breast cancer subtypes in a dose-dependent
fashion
AMPKα has been implicated as a tumor suppressor in breast cancer [6675]. Since FND-4b activated AMPKα, we measured its effects on the growth of
breast cancer cells and compared with AICAR—a known AMPK activator. Cell
counting assays showed that treatment at 5 µM FND-4b for 72 h resulted in
significant growth inhibition of MCF-7, T-47D, MDA-MB-231, HCC-1806, and
breast cancer stem cells (Figure 2.3A). Similar decreases occurred in all breast
cancer subtypes with 5 µM treatment. Treatment at a much higher concentration
of AICAR (1 mM) for 72 h yielded growth reductions similar to FND-4b among all
subtypes (Figure 2.3B). The most striking differences were that MCF-7 cells were
more sensitive to FND-4b while HCC-1806 cells were more responsive to
AICAR. Only small differences were noted among T-47D, MDA-MB-231, and
breast cancer stem cells. In addition, SRB growth assays indicated that treatment
at various FND-4b concentrations (2.5, 5, 10, and 20 µM) for 72 h yielded
significant dose-dependent decreases in proliferation of MCF-7, T-47D, MDAMB-231, and HCC-1806 cells (Figure 2.3C). ER+BC cells were more sensitive
than TNBC cells to FND-4b at 2.5 µM, but the reductions were similar at higher
concentrations. Similar growth inhibition at the 5 µM dosage between ER+BC
and TNBC is consistent with the results from the cell counting assays. Taken
together, these results illustrate that activation of AMPKα with FND-4b resulted in
dose-dependent decreases in growth in ER+BC and TNBC.
2.4.4 FND-4b increased apoptosis in ER+BC and TNBC
While FND-4b’s major effect is on cell growth, its treatment also increased
apoptosis in colon cancer [77]. Therefore, we investigated apoptosis induction in
breast cancer cells. As previously mentioned, treatment with FND-4b resulted in
increased levels of cleaved PARP, a marker of apoptosis, in MDA-MB-231, HCC1806, and MCF-7 cells (see Figure 2.2). We also measured apoptosis with
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ELISA cell death assays that are more sensitive than western blotting assays.
Significant increases in apoptosis were found in MCF-7 and T-47D cells—with
MCF-7 cells being more sensitive (Figure 2.4A). Apoptosis was significantly
increased in MDA-MB-231 cells with treatment at 10 µM FND-4b, but apoptosis
in HCC-1806 cells was not increased (Figure 2.4A). Finally, to determine whether
higher baseline pAMPK levels affect apoptosis in these cells, we compared the
basal rates of apoptosis among the four cell lines used in the ELISA assays.
HCC-1806 cells, which had the lowest pAMPK levels at baseline (Figure 2.1),
had a much higher basal apoptotic rate than the other three cell lines (Figure
2.4B). This indicates that higher baseline levels of pAMPK do not increase the
basal apoptotic rate. The elevated basal level of apoptosis in HCC-1806 cells is
likely the reason why FND-4b was unable to induce apoptosis in this cell line.
FND-4b’s ability to suppress growth of HCC-1806 cells resulted in fewer cells in
the treated wells compared to the control wells. As a result, there were less cells
that could have undergone apoptosis—resulting in lower readings in the treated
wells.
2.5 Discussion
The connection between AMPK activation and the inhibition of cancer cell
growth prompted our interest in targeting AMPK and its downstream signaling
pathways. AMPK activators such as AICAR and 2-DG have limited utility for
patient care due to their high dose requirements [50]. We focused on novel
small-molecule agents that activated AMPK at low concentrations and that stood
a greater chance than these well-known AMPK activators of progressing toward
the clinic. In this project, we examined the effects of the AMPK activator FND-4b
to determine its effects on ER+BC, TNBC, and breast cancer stem cells. FND-4b
previously suppressed the growth of colorectal cancer cells and stem cells
through ac5tivation of AMPK in the low micromolar range without affecting
signaling through the Akt or ERK pathways [77, 78]. We found that treatment with
FND-4b resulted in dose-dependent increases in AMPK activation in both breast
cancer subtypes and in the stem cells.
Other investigators have also focused on discovering novel AMPK
activators or repurposing current drugs that activate AMPK for breast cancer
therapy. OSU-53 and RL-71 activated AMPK and exerted anti-tumor effects in
TNBC at low micromolar doses [67, 72]. In addition, demethoxycurcumin (20 µM)
resulted in AMPK activation and large decreases in TNBC and ER+BC cell
proliferation [68]. Finally, treatment of TNBC with the anti-depressant fluoxetine
(0.5 µM) caused AMPK activation and substantial reductions in cellular viability
[71]. Taken together, these studies and ours suggest the merit in targeting the
AMPK signaling pathway for the treatment of breast cancer.
We found that low micromolar concentrations of FND-4b substantially
reduced the growth of TNBC. The decreases in proliferation that were induced by
5 µM FND-4b were similar to those caused by a much higher concentration of
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AICAR (1 mM). Although HCC-1806 cells were more responsive to AICAR in cell
counting assays, slightly higher concentrations of FND-4b (10 or 20 µM) should
suppress HCC-1806 growth more than 1 mM AICAR. The substantial growth
reductions that we found are particularly important because of the inherent
aggressiveness of TNBC that has higher rates of recurrence and metastasis than
other breast cancer subtypes [3]. The seriousness of TNBC is further amplified
by the fact that most breast cancer deaths result from metastatic lesions [2]. The
difficulty in developing treatments for TNBC is due to the lack of the estrogen
receptor and HER2 amplification. Drugs that target these proteins, such as
trastuzumab and tamoxifen, are ineffective in TNBC. Instead, patients with TNBC
typically receive a drug cocktail that damages normal cells in addition to the
tumor and leads to significant side effects. Current efforts are focused on
developing drugs that specifically target proteins or pathways that are exclusively
altered in TNBC. Since expression of AMPK and pAMPK is lower in breast
cancer than normal tissue, this signaling pathway attracted our attention as an
option for targeted therapy [61, 108, 109].
AMPK activation resulted in substantial decreases in cell proliferation in all
breast cancer subtypes that were tested. These reductions in growth were due to
AMPK’s ability to regulate the cell cycle both directly and indirectly. Directly,
AMPK activation can attenuate levels of cyclin D1, an important protein that
controls cell cycle arrest during the G1 phase [110]. Prior work in ovarian cancer
has suggested that AMPK activation causes degradation of cyclin D1 through a
pathway involving glycogen synthase kinase 3β [110]. Once cyclin D1 is
degraded, cells are prevented from progressing past the G1 phase [110]. We
found that FND-4b-induced AMPK activation resulted in substantial decreases in
cyclin D1 expression, resulting in cell cycle arrest. Indirectly, AMPK activation
can affect the cell cycle through effects on mTOR and cellular metabolism.
AMPK downregulates flux through the mTOR pathway, which can control the cell
cycle through its downstream effectors S6 kinase 1 (S6K1) and eukaryotic
translation initiation factor 4E-binding protein 1 [111]. In our study, we measured
mTOR activity by blotting for levels of phosphorylated ribosomal protein S6,
which is downstream from S6K1. We found decreases in S6 phosphorylation with
FND-4b-induced AMPK activation, indicating less mTOR flux and cell cycle
progression. Additionally, AMPK affects cell metabolism by phosphorylating and
inhibiting ACC, which is the rate-limiting step in fatty acid synthesis. As a result,
de novo lipogenesis is inhibited. Fatty acids are required for progression through
the cell cycle—notably, during the G1-S and G2-M phases—and in their absence,
cells will be unable to complete mitosis [54]. Instead they will be arrested at the
G2-M checkpoint [54]. We showed that FND-4b-induced AMPK activation led to
increased ACC phosphorylation, signifying less fatty acid synthesis and flux
through the cell cycle.
In addition to inducing cell cycle arrest, AMPK can also act as a tumor
suppressor by causing apoptosis [108]. We found that FND-4b causes apoptosis
in a dose-dependent manner in ER+BC cells with ELISA cell death assays. We
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also showed clear increases in levels of cleaved PARP—an apoptotic indicator—
in MCF-7 cells. TNBC cells were more resistant to apoptosis from FND-4b, but
there was apoptosis in MDA-MB-231 cells with 10 µM treatment. Additionally, we
found increases in cleaved PARP in MDA-MB-231 and HCC-1806 cells with
western blot. Taken together, these data indicate that ER+BC cells are more
susceptible to FND-4b-induced apoptosis than TNBC. However, as suggested in
previous work, the effects of FND-4b on cell cycle progression are more
pronounced and consistent than on apoptosis [77].
2.6 Conclusions
We have shown that the novel compound FND-4b can activate AMPK in
ER+BC, TNBC, and breast cancer stem cells. In addition, treatment with this
compound can dose-dependently decrease proliferation and increase apoptosis
in breast cancer cells. The effects on cellular growth are mediated via decreased
cell cycle flux—as evidenced by reductions in cyclin D1 levels—and suppression
of fatty acid synthesis and mTOR signaling. With such profound effects on
proliferation, further development of FND compounds could lead to their inclusion
in TNBC treatment regimens.
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Table 2.1 Primary and Secondary Antibody Information.
Antibody
Monoclonal
Host
Dilution Supplier
vs.
Species
Polyclonal
pAMPKα
Monoclonal
Rabbit
1:500
CST
Total
Polyclonal
Rabbit
1:1000
CST
AMPKα
pACC
Polyclonal
Rabbit
1:1000
CST
Total ACC
Monoclonal
Rabbit
1:1000
CST
pS6
Polyclonal
Rabbit
1:1000
CST
Total S6
Monoclonal
Rabbit
1:1000
CST
Cyclin D1
Monoclonal
Rabbit
1:2500
Abcam
PARP
Monoclonal
Rabbit
1:1000
CST
Beta-actin
Monoclonal
Mouse
1:10000
SigmaAldrich
Rabbit
Goat
1:10000
Santa
Cruz
Mouse
Goat
1:10000
Santa
Cruz

Catalogue
Number
2535
2532
3661
3676
2211
2217
ab134175
9532
A1978
sc-2054
sc-2055
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Figure 2.1 Examination of pAMPKα levels in breast cancer subtypes.
Equal numbers of MCF-7, T-47D, HCC-1143, MDA-MB-231, and HCC-1806 cells
were incubated overnight before cell lysis. Western blot analyses were performed
for total and phosphorylated forms of AMPKα and ACC. Beta-actin was used as
the loading control.
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Figure 2.2 FND-4b activated AMPKα and its downstream signaling
pathways in a dose-dependent manner in breast cancer.
Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer
stem cells were treated with fresh medium that contained different FND-4b
concentrations (0, 1, 2.5, 5, 10, and 20 µM) for 24 h. Western blot analysis was
then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as
well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control.
Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα
activation at the 5 µM dosage with subsequent decreases at higher
concentrations.
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Figure 2.3 AMPKα activation with FND-4b decreased proliferation of breast
cancer cells with similar efficacy to AICAR.
(A) Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806, or breast cancer
stem cells were grown in medium containing 0 or 5 µM FND-4b for 72 h followed
by cell counting. (B) The same procedure described in (A) was followed with the
exception of growing cells in medium containing 0 or 1 mM AICAR instead. (C)
MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were grown in medium
containing different concentrations of FND-4b (0, 2.5, 5, 10, and 20 µM) for 72 h
before SRB growth assays were performed. Data are presented as mean ± SD
from experiments performed in triplicate (cell counting) or sextuplicate (SRB
assays) and are representative of three independent experiments. * indicates pvalue < 0.01.
26

Figure 2.4 AMPKα activation with FND-4b increased apoptosis of breast
cancer cells.
(A) Equal numbers of MCF-7, T-47D, MDA-MB-231, or HCC-1806 cells were
cultured in medium containing different concentrations of FND-4b (0, 2.5, 5, and
10 µM) for 72 h before ELISA cell death assays were performed. (B) The basal
apoptotic rates of MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were
compared using the control data from the ELISA cell death assays in (A). Data
are presented as mean ± SD from an experiment performed in triplicate and are
representative of three independent experiments. * indicates p-value < 0.001.
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CHAPTER 3. TARGETING PI3K AND AMPKα SIGNALING ALONE OR IN
COMBINATION TO ENHANCE RADIOSENSITIVITY OF TRIPLE NEGATIVE
BREAST CANCER
3.1 Abstract
Triple negative breast cancer (TNBC) is the most aggressive breast
cancer subtype and is characterized by poor survival. Radiotherapy plays an
important role in treating TNBC. The purpose of this study was to determine
whether inhibiting the AMP-activated protein kinase (AMPK) and
phosphatidylinositol 3-kinase (PI3K) pathways alone or in combination
potentiates radiotherapy in TNBC. AMPKα1 and AMPKα2 knockdown diminished
cyclin D1 expression and induced G1 cell cycle arrest but did not induce
apoptosis alone or in combination with radiotherapy. Next, we analyzed the role
of PI3K p85α, p85β, p110α, p110β, Akt1, and Akt2 proteins on TNBC cell cycle
progression and apoptosis induction. Akt1 and p110α knockdown diminished
cyclin D1 expression and induced apoptosis. Silencing Akt1 promoted synergistic
apoptosis induction during radiotherapy and further reduced survival after
radiation. Treatment with the Akt inhibitor, MK-2206 48 h after radiotherapy
decreased Akt1 levels and potentiated radiation-induced apoptosis. Together,
our results demonstrate that AMPKα, p110α, and Akt1 promote TNBC
proliferation and that Akt1 is a key regulator of radiosensitivity in TNBC.
Importantly, combining radiotherapy with the pharmacological inhibition of Akt1
expression is a potentially promising approach for the treatment of TNBC.
3.2 Introduction
Breast cancer is the most common and second deadliest cancer among
women worldwide [4]. The most aggressive subtype is triple negative breast
cancer (TNBC), which makes up about 15-20% of cases [3, 4]. TNBC is
characterized by a lack of expression of the estrogen receptor, progesterone
receptor, and HER2 [2, 4]. It affects a younger patient population, metastasizes
at a higher rate than other subtypes, and has a poor prognosis [3, 4]. Tumor
analysis has revealed four separate subtypes of TNBC [13]. Due to this
heterogeneity, the development of targeted therapies for TNBC has largely been
unsuccessful [5]. Standard approaches involve chemotherapy, which can be
combined with surgery and/or radiation, but improvements still need to be made
[3, 4]. Radiosensitization, which involves combining radiotherapy with an agent
that can potentiate its effects, is a potential advancement that warrants further
study in TNBC.
Radiation improves survival in TNBC patients [33, 34] by inducing singleand double-stranded DNA breaks through direct DNA damage or via the
generation of free radicals [112-114]. Radiated cells respond to this by activating
stress, survival, and metabolic pathways, and repair enzymes attempt to fix
damaged DNA [112-114]. If the DNA is not successfully repaired, then the
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apoptotic cascade will be induced and lead to cell death [112-114]. Blocking
cellular pathways that control metabolism or survival may prevent cells from
adequately repairing damaged DNA, thereby enhancing apoptosis induction and
leading to radiosensitization. Two proteins that play important roles in
metabolism and survival are AMP-activated protein kinase (AMPK) and
phosphatidylinositol 3-kinase (PI3K), respectively. Furthermore, a doublenegative feedback loop exists between AMPK and Akt, a major downstream
effector of PI3K, in breast cancer [115].
AMPK is a heterotrimer that is made up of a catalytic subunit (α) and two
regulatory subunits (β and γ) [44, 46-48, 50, 52, 53, 56]. The catalytic subunit
consists of α1 and α2 isoforms [44, 46-48, 50, 52, 53, 56]. AMPK is a major
metabolic regulator that is activated during low energy states and helps cells
return to energy homeostasis by increasing ATP production and reducing ATP
consumption [44, 46-48, 50, 52, 53, 56]. Radiotherapy induces cellular stress and
has led to AMPK activation in cancer cells [80, 85]. Moreover, AMPK has
provided a survival benefit in esophageal and nasopharyngeal carcinoma cells
exposed to radiation by mediating autophagy induction [84, 85]. Furthermore,
levels of phosphorylated and total AMPK were upregulated in radiation-resistant
colon cancer cells and tissue—with AMPK knockdown sensitizing radiationresistant cells to radiotherapy [86]. PI3K is a heterodimer that promotes cellular
growth and survival by activating Akt, which subsequently activates the
mammalian target of rapamycin (mTOR) [92-95, 116]. PI3K is composed of a
catalytic subunit (p110α or p110β) and a regulatory subunit (p85α or p85β) [93,
95, 116]. Akt is composed of three isoforms: Akt1, Akt2, and Akt3 [92, 94]. The
PI3K/Akt/mTOR pathway is the most altered pathway in breast cancer, and
almost 30% of TNBC cases have PI3K alterations [96, 97]. Studies have
indicated that 20-25% of these changes were due to mutations in PIK3CA, which
is the gene for p110α [96, 97]. Since this signaling cascade promotes survival, it
has also been targeted in efforts to induce radiosensitivity. Chemical inhibition of
PI3K or mTOR signaling—alone or in combination—sensitized estrogen
receptor-positive breast cancer and TNBC to radiotherapy [98-102]. In addition,
ectopic expression of Akt1 promoted radioresistance in estrogen receptorpositive breast cancer [103]. However, targeting individual AMPK isoforms, PI3K
subunits, or Akt isoforms—alone or in combination—to enhance the effects of
radiation in TNBC has not previously been done.
In the present study, we investigated the role of AMPK and the PI3K/Akt
pathway in TNBC radiation sensitivity and examined whether combination
therapy can improve treatment response to radiation therapy. We determined
that both Akt1 and p110α promote proliferation and prevent apoptosis in TNBC
cells. Next, we established that knockdown of Akt1 enhances radiation-induced
apoptosis in TNBC cells and decreases survival of TNBC cells after radiation.
Knockdown of AMPKα1 or AMPKα2 did not enhance radiation-induced apoptosis
alone or in combination with Akt1 knockdown. Finally, we showed that treatment
with the Akt inhibitor MK-2206 reduces Akt1 expression and promotes synergistic
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apoptosis induction with radiotherapy in a schedule-dependent manner.
Targeting Akt1 expression at the initiation of radiation-induced apoptosis could
improve TNBC patient outcomes, reduce toxicity associated with PI3K/mTOR
inhibition, and mitigate side effects from radiotherapy.
3.3 Materials and methods
3.3.1 Materials
Roswell Park Memorial Institute (RPMI) 1640 medium was from Thermo
Fisher (Waltham, MA). Dulbecco’s Modified Eagle Medium (DMEM) was from
Corning (Corning, NY). DMEM/F12 was from Sigma-Aldrich (St. Louis, MO).
Fetal bovine serum (FBS), 100x penicillin-streptomycin solution (PS), 10 mg/mL
insulin solution, 100x non-essential amino acid solution, and Dulbecco’s
Phosphate Buffered Saline (PBS) were from Sigma-Aldrich. Opti-MEM and
Lipofectamine RNAiMAX were from Thermo Fisher. Protein Assay Dye was from
Bio-Rad (Hercules, CA). Amersham ECL Prime Western Blotting Detection
Reagent was from GE Healthcare Life Sciences (Chicago, IL). Immobilon
Western Chemiluminescent HRP Substrate was from Millipore (Burlington, MA).
Pooled siRNAs for AMPKα1 and AMPKα2 were from Santa Cruz Biotechnology
(Dallas, TX). Pooled siRNAs for Akt1, Akt2, p110α, p110β, p85α, and p85β were
from Thermo Fisher. The CytoscanTM SRB Cell Cytotoxicity Assay was from GBiosciences (St. Louis, MO). The Propidium Iodide Flow Cytometry Kit for Cell
Cycle Analysis was from Abcam (Boston, MA). MK-2206 2HCl, A-674563,
AZD5363, and Perifosine were from Cayman Chemical (Ann Arbor, MI). Primary
antibodies used in this study include: Abcam: (1) AMPKα1, ab32047 (1:1000 for
WB, 1:100 for IHC for PDXs, and 1:175 for IHC for whole tissue sections), (2)
AMPKα2, ab3760 (1:1000 for WB, 1:200 for IHC for PDXs, and 1:300 for IHC for
whole tissue sections), (3) Cyclin D1, ab134175 (1:2500 for WB); Cell Signaling
Technology (Danvers, MA): (1) pAkt, #4060 (1:2000 for WB), (2) Akt1, #75692
(1:1000 for WB), (3) Akt2, #3063 (1:1000 for WB), (4) p110α, #4249 (1:1000 for
WB), (5) p110β, #3011 (1:1000 for WB), (6) Cleaved PARP, #5625 (1:1000 for
WB), (7) Caspase-3, #9664 (1:1000 for WB), (8) p53, #2527 (1:1000 for WB), (9)
pDNA-PKcs, #68716 (1:1000 for WB), (10) DNA-PKcs, #12311 (1:1000 for WB),
(11) pAMPKα, #50081 (1:1000 for WB), and (12) AMPKα, #5831 (1:1000 for
WB); Santa Cruz Biotechnology: (1) p85α, sc-71891 (1:1000 for WB), (2) p85β,
sc-515646 (1:1000 for WB); and Sigma-Aldrich: β-actin (1:10,000 for WB).
Secondary antibodies were from Santa Cruz Biotechnology.
3.3.2 Cell Culture
MDA-MB-175, MDA-MB-231, MDA-MB-453, MDA-MB-468, HCC-1143,
HCC-1806, BT-20, BT-549, and HS-578T cells were from the American Type
Culture Collection. All cells were cultured in a humidified incubator at 37°C and
5% CO2. MDA-MB-231, MDA-MB-453, HCC-1143, and HCC-1806 cells were
cultured in RPMI-1640 + 10% FBS + 1% PS. BT-549 cells were cultured in
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RPMI-1640 + 10 µg/mL insulin + 10% FBS + 1% PS. HS-578T cells were
cultured in DMEM + 10 µg/mL insulin + 10% FBS + 1% PS. BT-20 cells were
cultured in DMEM + 1x Amino Acids + 10% FBS + 1% PS. MDA-MB-175 cells
were cultured in DMEM + 10% FBS + 1% PS. MDA-MB-468 cells were cultured
in DMEM/F12 + 10% FBS + 1% PS.
3.3.3 siRNA Transfection
TNBC cells were transfected with siRNA to NTC, AMPKα1, AMPKα2,
p110α, p110β, p85α, p85β, Akt1, or Akt2. The final siRNA concentration used in
each experiment is indicated in the relevant descriptions. The siRNAs were
mixed with Lipofectamine RNAiMAX in Opti-MEM for 20 min. The ratio of OptiMEM to complete medium was 1:4. Medium was changed every 24 h until cell
lysis or subsequent seeding for downstream applications.
3.3.4 Radiation Treatment
(I) In time-course and dose-response experiments, MDA-MB-231 cells
were irradiated at the indicated doses with an X-RAD 225XL (Precision X-Ray,
North Branford, CT) at the X-ray Service Center of the Department of Toxicology
& Cancer Biology. The X-ray beam setting was 225 kVp with 0.3 mm Cu filtration.
The beam output was calibrated following AAPM TG-61 protocol with
measurement done in-air. An A1SL ion chamber (Standard Imaging, Madision,
WI) was used which is calibrated at the University of Wisconsin Accredited
Dosimetry Calibration Laboratory (UW ADCL) in terms of air kerma (Gy/C).
Accurate absorbed doses to water were calculated by considering the impact of
backscattering as previously described [117]. Cells were lysed for
immunoblotting at the indicated times. (II) To establish radiation-induced
apoptosis induction, two methods were used. The first was a single radiation
dose (0, 6, or 10 Gy) followed by incubation at 37°C and 5% CO2 for 48 h or 72 h
before lysis. The second was a fractionated approach in which cells were
irradiated at the same dose (0, 2, 4, or 6 Gy) daily for 4 d with lysis occurring 24
h after the last dose. (III) MDA-MB-231 cells were transfected with siRNA to
NTC, AMPKα1, Akt1, or AMPKα1/Akt1. Transfection concentrations were: (1)
individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM total), and
(3) siNTC: 100 nM. Cells were irradiated at the indicated doses either on the
same day as transfection or 24 h after transfection. Cells were incubated at 37°C
and 5% CO2 for 72 h after transfection before lysis for immunoblotting.
3.3.5 Analysis of Glycolytic Rate
MDA-MB-231 cells were transfected with 50 nM siRNA to NTC, AMPKα1,
or AMPKα2. Medium was changed after 24 h, and cells were seeded into
Seahorse XF96 Cell Culture Microplates at a density of 20,000 cells per well after
48 h. At 72 h post transfection, the Redox Metabolism Shared Resource Facility
at the University of Kentucky measured the glycolytic rate with a Seahorse
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XFe96 Analyzer (Agilent, Santa Clara, CA). The Glycolytic Rate Assay was
conducted according to the manufacturer’s protocol [118]. Cells were initially
treated with 0.5 μM rotenone and 0.5 μM antimycin A before a final injection of
50 mM 2-deoxy-D-glucose. Analysis was performed with the Agilent Seahorse
Wave Desktop software. Measurements of the glycolytic rate were based on the
Glycolytic Proton Efflux Rate (glycoPER). The buffer factor was set to 2.4
mmol/L/pH, and data were normalized to μg protein in each well.
3.3.6 Immunoblotting
TNBC cells were seeded and transfected as described above. Final
concentrations were 50 nM or 100 nM, as indicated in the appropriate figures.
After 72 h, medium was removed, and cells were washed with ice cold 1x PBS.
Cells were then scraped and lysed in 1x radioimmunoprecipitation assay (RIPA)
buffer containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were
incubated on ice for 20 min with 10-sec vortexes every 5 min before
centrifugation at 14,000 rpm for 20 min at 4°C. Protein concentrations in the
lysates were then determined. Equal amounts of protein were reduced and
denatured by heating at 80°C for 10 min before being resolved on 4-12% Bis-Tris
gels. The proteins were then transferred to polyvinylidene fluoride (PVDF)
membranes, blocked with 10% milk for at least 1 h, and incubated in primary
antibody solutions overnight at 4°C. On the next day, the membranes were
washed twice with 1x Tris-buffered saline with Tween 20 (TBST) for 5 min and 10
min before incubation with secondary antibody solutions (1:10,000 dilutions) for 1
h at room temperature. The membranes were then washed twice with TBST for
15 min and 20 min before Amersham ECL or Immobilon were added to the
membranes for protein detection. Stripping buffer was used on membranes
where required.
To determine apoptosis induction after radiation, the above procedure was
modified. First, to include floating cells that had undergone apoptosis, the
medium at 48 h post transfection was saved and frozen at 80°C until cell lysis. At
the time of lysis, cells were scraped before medium removal, combined with the
previously frozen medium, and centrifuged at 14,000 rpm for 5 min at 4°C. The
medium was then suctioned off, and the remaining pellet was washed with 1x
PBS and centrifuged at 14,000 rpm for 5 min at 4°C. After removing the PBS, the
cells were lysed with 1x RIPA buffer containing 1 mM PMSF as described above.
3.3.7 Cell Counting Assay
MDA-MB-231 cells were transfected with 50 nM siRNA to NTC, AMPKα1,
or AMPKα2 as described above. Medium was changed after 24 h. After 48 h,
cells were washed with 1x PBS, trypsinized, and counted with a Beckman
Coulter Vi-Cell XR. Then equal numbers of each transfected cell (0.1 x 106 cells
per well) were seeded in 6-well plates and incubated under normal cell culture
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conditions. Medium was changed after 72 h, and cell counting was performed
after 96 h with the same instrument.
3.3.8 Sulforhodamine B (SRB) Assay
MDA-MB-231 cells were transfected with siRNA to NTC, AMPKα1,
AMPKα2, Akt1, or p110α (including combinations). Transfection concentrations
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM
total), and (3) siNTC: 100 nM. Medium was changed after 24 h, and equal
numbers of each transfected cell (3,000 cells per well) were seeded in 96-well
plates after 48 h. Cells were allowed to incubate under normal cell culture
conditions for 48 h. Cells were then fixed, stained, and quantified following the
CytoscanTM SRB Cell Cytotoxicity Assay protocol.
3.3.9 Colony Formation Assay
MDA-MB-231 cells were transfected with siRNA to NTC, AMPKα1, Akt1,
or AMPKα1/Akt1. Transfection concentrations were: (1) individual siRNA: 50 nM,
(2) combination siRNA: 50 nM each (100 nM total), and (3) siNTC: 100 nM. After
48 h, cells were seeded at equal density in 96-well plates (100 cells/well). Cells
were then exposed to radiation (0 or 4 Gy) on the following day. After 7 days,
cells were fixed, stained, and quantified following the SRB Assay protocol
described above.
3.3.10 Flow Cytometry
MDA-MB-231 cells were transfected with 50 nM siRNA to NTC, AMPKα1,
or AMPKα2 as described above. Medium was changed after 24 h, and cells were
seeded into separate 10-cm plates after 48 h. On the following day, cells were
collected, fixed in 66% ethanol, and stored at 4°C for at least 2 h. Before
analysis, cells were rehydrated in PBS and stained with a solution containing
propidium iodide and RNase for 30 min at 37°C in the dark. Analysis of DNA
content was performed by measuring the propidium iodide fluorescence intensity
with a flow cytometer in the Flow Cytometry and Immune Monitoring Core at the
University of Kentucky.
3.3.11 Immunohistochemistry
TNBC whole tissue samples were selected by the Markey Cancer Center
Biospecimen Core. 4-μm slides were deparaffinized and hydrated stepwise.
Antigen retrieval was carried out in a Biocare Medical decloaking chamber at
95°C for 20 min, followed by quenching of endogenous peroxidase activity and
incubation with primary antibody overnight at 4°C. The slides were subsequently
incubated with Vector Laboratories ImmPRESS® anti-rabbit HRP polymer for 30
min at room temperature and staining was visualized with DAB (Dako). Antibody
specific conditions were as follows: (1) AMPKα1: Dako high pH antigen retrieval
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buffer; 10-min DAB incubation; 1:175 dilution and (2) AMPKα2: Dako low pH
antigen retrieval buffer; 5-min DAB incubation; 1:300 dilution. A pathologist who
was blinded to the stage of disease scored the samples for staining intensity and
distribution percentage on scales of 0-3. For staining intensity: 0 = negative; 1 =
weak; 2 = moderate; and 3 = strong. For distribution percentage: 0 = 0%; 1 = 110%; 2 = 11-50%; and 3 = 51-100%.
TNBC patient-derived xenografts (PDXs) were from Dr. Kathleen
O’Connor’s laboratory and were immunostained as described above except the
AMPKα1 dilution was 1:100 and the AMPKα2 dilution was 1:200.
3.3.12 Statistical Analysis
Descriptive statistics including means and standard deviations (SD) are
presented in each experimental group and displayed in bar graphs. Comparisons
of WB, proliferation, oxidative stress markers, and SRB absorbance were
performed using the one sample t-test, one way and two-way analysis of
variance (ANOVA) with Holm's adjustment for multiple testing between groups.
For the combination studies, a two-way ANOVA with factors for
AMPKα1/AMPKα2 knockdown and Akt1 or p110α treatments along with
interaction between factors was used. Likewise, two-way ANOVA with an
interaction term was utilized to account for the differential effect of radiation in the
comparison of AMPKα1/AMPKα2 knockdown and Akt1 single and combination
groups. p<0.05 was considered to indicate a statistically significant difference.
Statistical analyses were performed using SAS software version 9.4 (SAS Inc.,
Cary, NC, USA).
3.4 Results
3.4.1 Analysis of AMPKα1 and AMPKα2 expression in TNBC patient samples,
cell lines, and PDXs
AMPK is an important regulator of cellular metabolism that has recently
gained attention as a potential target in cancer therapy. The catalytic subunit is
composed of α1 and α2 isoforms; expression of the individual isoforms has not
been studied in TNBC. Therefore, we initially examined expression of AMPKα1
and AMPKα2 isoforms in TNBC patient samples, cell lines, and PDXs.
Representative IHC staining of both AMPKα1 and AMPKα2 in patient samples is
shown in Figure 3.1A. In these images, AMPKα1 was expressed in the cytoplasm
while AMPKα2 was expressed in both the nucleus and cytoplasm. Figure 3.1B
indicates the scoring distribution of AMPKα1 and AMPKα2 among the patient
samples. Each sample received a score of 4, 5, or 6 for both AMPKα1 and
AMPKα2, indicating strong and/or widespread expression in each tumor. Next,
cellular localization of AMPKα1 and AMPKα2 was compared in these patient
samples. As shown in Figure 3.1C, AMPKα1 was expressed only in the
cytoplasm, while AMPKα2 was found in both the cytoplasm and the nucleus.
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Immunoblotting was then used to study the expression of both isoforms in a
panel of TNBC cell lines (Figure 3.1D). AMPKα1 was expressed in all cell lines
with the lowest level in MDA-MB-453 cells, but AMPKα2 expression was more
variable. MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-20, and MDA-MB-175
cells had high AMPKα2 expression, while BT-549, HS-578T, HCC-1806, and
HCC-1143 cells had low AMPKα2 expression.
We extended our analysis to include AMPKα1 and AMPKα2 expression in
TNBC PDX samples. Representative IHC staining of AMPKα1 and AMPKα2 in
TNBC PDX samples is shown in Figure 3.2A. In these images, AMPKα1 was
expressed in the cytoplasm while AMPKα2 was found in both the nucleus and
cytoplasm. The scoring distribution of AMPKα1 and AMPKα2 in the PDX
samples is indicated in Figure 3.2B. All samples were scored as 4, 5, or 6,
signifying strong and/or widespread expression. Analysis of isoform localization
was also done. As shown in Figure 3.2C, AMPKα1 was found only in the
cytoplasm, while AMPKα2 was expressed in both the nucleus and the cytoplasm.
Taken together, our results indicate that AMPKα1 and AMPKα2 are widely
expressed in TNBC with AMPKα2 predominantly localized to the nucleus.
3.4.2 AMPKα1 and AMPKα2 promote TNBC proliferation and cell cycle
progression
The individual roles of AMPKα1 and AMPKα2 isoforms in TNBC are not
well understood. Therefore, we examined how each isoform impacts proliferation
and metabolism in TNBC cells. Using siRNA transfection, levels of both AMPKα1
and AMPKα2 were successfully reduced after 72 h in MDA-MB-231, MDA-MB468, and BT-20 cells (Figure 3.3A). Knockdown of either isoform led to
decreased cyclin D1 levels in MDA-MB-231 and MDA-MB-468 cells, while only
AMPKα1 knockdown resulted in cyclin D1 suppression in BT-20 cells.
Densitometry analysis indicated statistically significant reductions in cyclin D1
with AMPKα1 knockdown in all 3 cell lines and with AMPKα2 knockdown in
MDA-MB-231 and MDA-MB-468 cells (Figure 3.4A).
We next determined whether AMPKα regulates cell cycle and proliferation
in MDA-MB-231 cells. Flow cytometry analysis established that knockdown of
either AMPKα1 or AMPKα2 led to G1 cell cycle arrest (Figure 3.3B). The tumor
suppressor p53 can prevent cells from progressing past G1, and knockdown of
either AMPKα1 or AMPKα2 led to increased expression of p53 (Figure 3.3C).
Densitometry analysis indicated that the increases in p53 were statistically
significant (Figure 3.4B). To evaluate whether the induced G1 cell cycle arrest
impacted MDA-MB-231 growth, a proliferation assay was then done. As shown in
Fig 2D, knockdown of either AMPKα1 or AMPKα2 resulted in statistically
significant decreases in MDA-MB-231 proliferation.
Glycolytic activity increases during the G1 phase, and AMPK has been
shown to affect the cellular glycolytic rate [60, 62, 119]. Therefore, the effect that
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AMPKα1 or AMPKα2 knockdown has on glycolysis in MDA-MB-231 cells was
determined. Figure 3.3E indicates that knockdown of AMPKα1—but not
AMPKα2—decreased the glycolytic rate in MDA-MB-231 cells. The decreases in
glycolytic flux with AMPKα1 knockdown were statistically significant for both
basal and compensatory glycolysis (Figures 3.5A and 3.5B). Taken together, our
results indicate that both AMPKα1 and AMPKα2 promote cell cycle progression
and proliferation of MDA-MB-231 cells by potentially downregulating p53
expression while AMPKα1 also facilitates glycolytic flux.
3.4.3 Knockdown of Akt1 or p110α induces apoptosis and reduces proliferation in
MDA-MB-231 cells
The impact of individual PI3K subunits or Akt isoforms on TNBC
proliferation or apoptosis has not been studied. The effect of combined inhibition
of PI3K and AMPKα on TNBC growth and survival is also unknown. Therefore,
we examined how knockdown of PI3K signaling components—alone or in
combination with AMPKα isoforms—affected apoptosis induction and
proliferation in MDA-MB-231 cells. Initially, siRNA was used to establish
knockdown of p110α, p110β, p85α, p85β, Akt1, and Akt2. Figures 3.6A and 3.6B
shows siRNA knockdown of all components at 72 h and 96 h, respectively.
Knockdown of all proteins except p85β was accomplished at 72 h (Figure 3.6A),
while knockdown of p85β was confirmed at 96 h (Figure 3.6B). At both 72 h and
96 h, suppression of Akt1 and p110α led to the largest decreases in cyclin D1
and the most substantial increases in cleaved PARP.
Next, the effect of combined knockdown of PI3K and AMPKα on apoptosis
induction and proliferation in MDA-MB-231 cells was determined. As shown in
Figure 3.6C, PARP cleavage is induced with Akt1 knockdown alone or in
combination with knockdown of AMPKα1 or AMPKα2 in MDA-MB-231 cells.
Slight increases in PARP cleavage were also found with knockdown of p110α by
itself or when combined with knockdown of AMPKα2. In addition, an SRB growth
assay was performed to establish whether combined knockdown of AMPKα
isoforms with Akt1 or p110α suppressed MDA-MB-231 proliferation more than
knockdown of each protein alone. Single knockdown of AMPKα1, AMPKα2, Akt1,
or p110α significantly reduced MDA-MB-231 growth (Figure 3.6D). Additionally,
MDA-MB-231 proliferation was further decreased when knockdown of AMPKα1
was combined with knockdown of either Akt1 or p110α. However, the growth of
MDA-MB-231 cells was not further suppressed when AMPKα2 knockdown was
combined with knockdown of either Akt1 or p110α. Taken together, our results
indicate that silencing either Akt1 or p110α induces apoptosis and suppresses
proliferation of MDA-MB-231 cells—and combination knockdown with AMPKα1
further reduces growth.
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3.4.4 Radiotherapy increases activated and total AMPKα in MDA-MB-231 cells
AMPK has been activated in cancer cells by radiation and has increased
survival through the autophagy pathway [80, 84, 85]. However, the ability of
radiotherapy to activate AMPK in TNBC in unknown. Therefore, we established
whether radiation leads to AMPKα activation in MDA-MB-231 cells. Figure 3.7A
indicates that AMPKα was activated 1 h after exposure to increasing doses of
radiation (4, 6, and 8 Gy). AMPKα was activated to a similar degree at each
dose, indicating that the effect was not dose-dependent. In addition, levels of
total AMPKα were increased at every dosage. DNA-dependent protein kinase
(DNA-PK) is a DNA repair enzyme that was also activated at each radiation
dose. Figure 3.7B shows that 6 Gy radiation activated AMPK in MDA-MB-231
cells 1 h and 2 h post exposure—with the largest increase at 1 h. However,
pAMPK levels returned to baseline at 4 h and were not elevated at 24 h. Total
AMPKα was also slightly increased 1 h and 2 h after radiation treatment. DNAPK phosphorylation was detected after 1 h and decreased in a stepwise fashion
at 2 h, 4 h, and 24 h post exposure. Taken together, our results indicate that
radiation increases activated and total levels of AMPKα in a non-dose-dependent
manner in MDA-MB-231 cells.
3.4.5 Akt1 knockdown potentiates radiation-induced apoptosis and further
suppresses survival after radiation in MDA-MB-231 cells
Radiotherapy causes DNA damage, stress, and apoptosis. However,
activation of AMPK and Akt may help cells adapt to—and eventually overcome—
these stressful conditions. Therefore, we evaluated how knockdown of AMPKα1
and Akt1—alone or in combination—impacts radiation-induced apoptosis in
MDA-MB-231 cells. Attempts were initially made to determine when apoptosis is
induced in MDA-MB-231 cells following radiotherapy. Two approaches were
used: (1) a single dose of radiation followed by lysis after 48 h or 72 h or (2) a
fractionated approach in which cells were radiated at the same dose for 4
consecutive days and harvested 24 h after the last treatment (96 h after the first
dose). As shown in Figure 3.8A, a single dose of 6 or 10 Gy induced cleavage of
PARP and caspase-3 after 72 h in MDA-MB-231 cells. In addition, a single dose
of 10 Gy slightly induced PARP cleavage after 48 h. In Figure 3.8B, fractionated
dosing (2, 4, or 6 Gy daily for 4 d) also led to strong PARP and caspase-3
cleavage after 96 h total in MDA-MB-231 cells.
To determine whether combined knockdown of AMPKα1 and Akt1
potentiates radiation-induced apoptosis, a single radiation dosing scheme similar
to that in Figure 3.8A was used instead of the fractionated approach. Figure 3.8C
indicates that 6 Gy radiation induced PARP cleavage after 48 h and that this was
substantially enhanced when combined with 72 h Akt1 knockdown. However,
knockdown of AMPKα1 alone or in combination with Akt1 did not enhance this
effect. These findings were verified in Figure 3.9A. As shown in Fig 5D, similar
results were observed when radiating with 4 Gy and incubating for 72 h. PARP
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cleavage was induced with 4 Gy radiation alone after 72 h but was enhanced
when radiation was combined with 72 h Akt1 knockdown. As with the 48 h
timepoint, AMPKα1 knockdown alone or in combination with Akt1 did not
potentiate the increases in PARP cleavage. The effect of Akt1 silencing on MDAMB-231 survival after radiation was also examined. Either Akt1 knockdown or
treatment with 4 Gy radiation significantly reduced colony formation of MDA-MB231 cells, and survival was further suppressed in radiated cells with Akt1
knockdown (Figure 3.9B). Knockdown of AMPKα1 slightly attenuated the effect
of Akt1 knockdown at both 0 Gy and 4 Gy. Taken together, our results indicate
that silencing Akt1 sensitizes MDA-MB-231 cells to radiation-induced apoptosis
and decreases survival after radiotherapy.
3.4.6 MK-2206 treatment enhances radiation-induced apoptosis in MDA-MB-231
cells
To increase the clinical relevance of our findings, we examined the effect
of Akt inhibitors MK-2206, A-674563, AZD5363 and Perifosine on apoptosis
induction in MDA-MB-231 cells after radiation. Cells were treated with Akt
inhibitors 48 h after radiation exposure (Figures 3.8E and 3.8F). Treatment with
MK-2206 alone for 24 h reduced Akt1 expression and induced PARP cleavage in
MDA-MB-231 cells. In cells that were exposed to 4 Gy radiation, treatment with
MK-2206 synergistically increased PARP cleavage compared to either modality
alone. Administration of Perifosine also reduced Akt1 expression but did not
synergistically increase radiation-induced apoptosis. Treatment with other Akt
inhibitors—A-674563 or AZD5363—did not reduce Akt1 levels or induce
apoptosis. Taken together, our results indicate that reducing Akt1 expression
with MK-2206 at the initiation of apoptosis can potentiate the effect of
radiotherapy. Targeting Akt1 expression as a radiosensitizer in TNBC could
enhance patient outcomes and mitigate toxicity associated with both PI3K
pathway inhibition and radiotherapy.
3.5 Discussion
Triple-negative breast cancer (TNBC) (estrogen receptor-negative,
progesterone receptor-negative, and HER2-negative) is an aggressive subgroup
of breast cancer [3, 4]. Treating patients with TNBC remains clinically
challenging; radiation therapy is able to improve locoregional control in breast
cancer patients both after breast conserving surgery or mastectomy, with positive
impact on long-term survival [33, 34]. Radiotherapy’s importance as a treatment
modality in TNBC prompted our interest in attempting to further increase survival
advantage of radiotherapy in TNBC patients. We targeted two important cellular
pathways, AMPK and PI3K/Akt, with the hypothesis that their combined inhibition
would potentiate radiation-induced apoptosis.
The expression and function of individual AMPKα isoforms in TNBC has
not previously been studied. We demonstrated that both AMPKα1 and AMPKα2
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were expressed in TNBC patient samples, cell lines, and PDXs. AMPKα1 was
localized to the cytoplasm, while AMPKα2 was expressed in both the cytoplasm
and the nucleus. AMPKα2 expression has been shown to be enriched in the
nucleus compared to AMPKα1 in rat insulinoma cells [120]. AMPKα controls
cellular proliferation and glycolytic flux in TNBC [60, 62], but distinctions have not
been made between the two isoforms. We found that both AMPKα1 and
AMPKα2 promote proliferation and cell cycle progression of MDA-MB-231 cells.
We also determined that knockdown of either AMPKα1 or AMPKα2 led to
upregulation of p53, a tumor suppressor that can induce cell cycle arrest.
Although silencing AMPKα2 in BT-20 cells did not reduce cyclin D1 expression,
we suspect that this may be due to insufficient knockdown. Our densitometry
calculations indicated a trend toward reduced cyclin D1 expression in BT-20 cells
with AMPKα2 knockdown, and we expect that a more robust knockdown would
yield results consistent with our other cell lines. Taken together, our results
suggest that AMPKα1 and AMPKα2 support proliferation of MDA-MB-231 cells
by potentially reducing p53 levels. In other cancer cells, increased AMPK activity
or expression has led to amplified p53 levels [63, 121]. AMPK has a complex
cellular role that can vary based on the method by which AMPK is manipulated.
For instance, TNBC growth can be suppressed by AMPK activation or with stable
AMPKα knockdown [62, 67]. Therefore, we attribute the difference in our findings
to using a knockdown model instead of drug-induced AMPK activation or
overexpression. To our knowledge, no studies have established a link between
knockdown of endogenous AMPKα expression and p53 levels in cancer cells.
Further work is needed to establish the mechanism by which AMPKα1 or
AMPKα2 regulates p53 expression in TNBC cells. Knockdown of AMPKα1 did
not enhance radiation-induced apoptosis, suggesting that inhibiting the AMPKα
pathway does not provide further benefit. However, there may be value in
examining the combination of AMPKα activation and radiation in TNBC. Other
studies have demonstrated an advantage of AMPKα activation during
radiotherapy [45, 79, 82, 83]. In particular, metformin—an AMPKα activator—has
been shown to increase cell death after radiation exposure in lung, esophageal,
and estrogen receptor-positive breast cancer cells [79, 82, 83]. This is partly due
to AMPK’s ability to inhibit mTOR signaling, so a combination approach with Akt1
knockdown could be examined [45, 82, 83]. Future work could evaluate the
ability of increased AMPKα activity—whether by genetic upregulation or chemical
activation—to sensitize TNBC cells to radiation.
The PI3K/Akt/mTOR pathway is altered more frequently than any other
pathway in breast cancer [96]. However, the effect of individual subunits or
isoforms on proliferation or apoptosis induction in TNBC is unknown. We found
that knockdown of either Akt1 or p110α reduced cyclin D1 expression and
increased cleaved PARP expression in TNBC cells. The other components—
Akt2, p110β, p85α, and p85β—had minimal effects on cyclin D1 expression or
PARP cleavage. We selected Akt1 as our main target for combination therapy
with radiation, because its knockdown alone induced a higher rate of apoptosis
compared to p110α knockdown. Other studies have also found that Akt1 is the
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most important Akt isoform at inhibiting apoptosis induction in breast cancer and
mouse myeloid cells [122, 123]. Suppressing Akt1 expression during
radiotherapy could be a valuable approach in treating TNBC that is refractory to
neoadjuvant chemotherapy (NAC). TNBC is initially treated with NAC to shrink
the tumor as much as possible before surgery. Radiotherapy may be initiated
after surgery in an attempt to induce death of resistant cells. Our data indicate
that suppressing Akt1 levels—possibly with MK-2206—may sensitize resistant
TNBC tumors to radiotherapy. To our knowledge, this is the first study to
establish a link between Akt1 expression and radiation-induced apoptosis in
TNBC. This strategy could reduce future recurrence and ultimately lead to better
outcomes for TNBC patients.
Apoptosis is one of the primary methods by which radiotherapy induces
cell death [114]. We demonstrate that the apoptotic cascade is not immediately
activated after radiation and it takes up to 48h after radiation therapy to detect
apoptosis in TNBC cells. Akt inhibition or knockdown right after radiation therapy
do not synergistically increase the effect of radiation therapy. However, we show
the potential for the selective sensitization of tumor cells to radiation therapy with
timed knockdown of Akt1 expression after radiation therapy. MK-2206 promoted
synergistic apoptosis induction when administered after radiotherapy, and we
expect drugs that strongly reduce Akt1 expression (similar to genetic knockdown)
will promote radiation-induced apoptosis to an even greater degree. The ability to
enhance the effect of radiation therapy by reducing Akt1 levels at the time of
initial radiation-induced apoptosis induction is a particularly significant finding and
should be of relevance to the design of clinical combination protocols. By timing
Akt inhibitor administration with radiation therapy, we can reduce the frequency
of Akt inhibitor administration and the amount of drug given to the patient with
TNBC. To our knowledge, this is the first study to identify that an Akt inhibitor can
be administered in a schedule-dependent manner to induce radiosensitivity in
TNBC cells. Selective targeting of Akt1 protein expression should also decrease
the severity of side effects associated with PI3K/Akt pathway inhibition. In
addition, reducing Akt1 expression to enhance radiotherapy may lessen the
number of treatments required to induce apoptosis or arrest tumor growth—
potentially making radiation more tolerable for TNBC patients.
In summary (Figure 3.8G), we established that silencing Akt1 sensitized
TNBC cells to radiation treatment. Knockdown of Akt1 potentiated apoptosis
induction after radiotherapy and further suppressed TNBC cell survival after
treatment. Administration of MK-2206 at the initiation of radiation-induced
apoptosis reduced Akt1 expression and enhanced radiation therapy effect in
TNBC cells. Importantly, combining radiotherapy with pharmacological inhibition
of Akt1 expression at the optimal timing is a potentially promising approach for
the treatment of TNBC that could improve TNBC response to radiotherapy and
limit toxicity associated with PI3K pathway inhibition.

40

3.6 Acknowledgements
The Markey Cancer Center’s Research Communications Office helped
prepare the figures. The Biostatistics and Bioinformatics Shared Resource
Facility of the Markey Cancer Center conducted formal statistical analyses. The
Flow Cytometry and Immune Monitoring Core performed the flow cytometry
analyses. The Redox Metabolism Shared Resource Facility of the Markey
Cancer Center conducted the Seahorse analyses. The Biospecimen
Procurement & Translational Pathology Shared Resource Facility of the Markey
Cancer Center acquired and stained tissue sections. All of the Shared Resource
Facilities of the Markey Cancer Center are supported by P30CA177558. Dr.
Quan Chen (Department of Radiation Medicine) and Dr. Tadahide Izumi
(Department of Toxicology & Cancer Biology) assisted with radiation treatment of
TNBC cells. Dr. Kathleen O’Connor (Department of Molecular & Cellular
Biochemistry) provided the TNBC PDX samples. This work was supported by
Daphne’s Legacy Breast Cancer Research Funds and by National Institutes of
Health (NIH) grant R01 CA195573 (to BME). JJ and ZC were supported by T32
ES007266 and T32 CA160003, respectively.
3.7 Citation
Johnson, J; Chow, Z; Napier, D; Lee, E; Weiss, HL; Evers, BM; Rychahou, P.
“Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance
Radiosensitivity of Triple Negative Breast Cancer.” Cells; 2020; 9(5); 1253.

41

Figure 3.1 Analysis of AMPKα1 and AMPKα2 expression in TNBC whole
tissue sections and established cell lines.
(A) Representative IHC staining of AMPKα1 and AMPKα2 in TNBC whole tissue
sections. (B) Scoring distribution of AMPKα1 and AMPKα2 in TNBC whole tissue
sections (n = 17). (C) Subcellular localization (nuclear, cytoplasmic, or both) of
AMPKα1 and AMPKα2 in TNBC whole tissue sections (n = 17). (D) Western blot
of AMPKα1 and AMPKα2 expression in a panel of established TNBC cell lines (n
= 9).
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Figure 3.2 Analysis of AMPKα1 and AMPKα2 expression in TNBC PDX
samples.
(A) Representative IHC staining of AMPKα1 and AMPKα2 in TNBC PDX
samples. (B) Scoring distribution of AMPKα1 and AMPKα2 in TNBC PDX
samples (n = 7). (C) Subcellular localization (nuclear, cytoplasmic, or both) of
AMPKα1 and AMPKα2 in TNBC PDX samples (n = 7).
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Figure 3.3 AMPKα1 and AMPKα2 impact proliferation and cell cycle
progression in TNBC cells.
(A) MDA-MB-231, MDA-MB-468, and BT-20 cells were transfected with 50 nM of
siRNA targeting AMPKα1 or AMPKα2. Expression of AMPKα1, AMPKα2, and
cyclin D1 was analyzed by western blot 72h after transfection. (B) MDA-MB-231
cells were transfected with 50 nM of siRNA targeting AMPKα1 or AMPKα2. Cells
were seeded into 10-cm plates 48h after transfection and collected for cell cycle
analysis 24h later. (C) MDA-MB-231 cells were transfected with 50 nM of siRNA
targeting AMPKα1 or AMPKα2. Expression of AMPKα1, AMPKα2, and p53 was
analyzed by western blot 72h after transfection. (D) MDA-MB-231 cells were
transfected with 50 nM of siRNA targeting AMPKα1 or AMPKα2. Cells were
plated at a density of 100,000 cells/well 48h after transfection and counted 96h
after plating. (E) MDA-MB-231 cells were transfected with 50 nM of siRNA
targeting AMPKα1 or AMPKα2. Cells were plated at a density of 20,000 cells/well
48h after transfection, and the glycolytic rate was analyzed 24h later (n = 18). For
2A-D, the results are representative of 3 independent experiments. For 2E, the
result is representative of 2 independent experiments. *indicates p-value <
0.0001. NTC; Non-targeting control was used as a negative control.
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Figure 3.4 Densitometry measurements of cyclin D1 and p53 after AMPKα1
or AMPKα2 knockdown in TNBC cells.
(A) MDA-MB-231, MDA-MB-468, and BT-20 cells were transfected with 50 nM of
siRNA targeting AMPKα1 or AMPKα2. Expression of cyclin D1 was analyzed by
western blot densitometry 72h after transfection (n = 3). (B) MDA-MB-231 cells
were transfected with 50 nM of siRNA targeting AMPKα1 or AMPKα2.
Expression of p53 was analyzed by western blot densitometry 72h after
transfection (n = 3). *indicates p-value < 0.05; NTC, Non-targeting control was
used as a negative control.
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Figure 3.5 Effect of AMPKα1 or AMPKα2 knockdown on basal and
compensatory glycolysis in MDA-MB-231 cells.
MDA-MB-231 cells were transfected with 50 nM of siRNA targeting AMPKα1 or
AMPKα2. Non-targeting control was used as a negative control. Cells were
seeded at a density of 20,000 cells/well 48h after transfection, and the rates of
(A) basal and (B) compensatory glycolysis were determined 24h later (n = 18).
The results are representative of 2 independent experiments. *indicates p-value
< 0.0001.
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Figure 3.6 Knockdown of Akt or p110α increases apoptosis and decreases
proliferation in MDA-MB-231 cells.
MDA-MB-231 cells were transfected with 100 nM of siRNA to Akt1, Akt2, p110α,
p110β, p85α, or p85β. Expression of Akt1, Akt2, p110α, p110β, p85α, p85β,
cyclin D1, and cleaved PARP was determined with western blot (A) 72h and (B)
96h after transfection. (C) MDA-MB-231 cells were transfected with siRNA to
AMPKα1, AMPKα2, Akt1, or p110α alone or in combinations. Transfection
concentrations were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM
each (100 nM total), and (3) siNTC: 100 nM. Expression of AMPKα1, AMPKα2,
Akt1, p110α, and cleaved PARP was determined with western blot 72h after
transfection. (D) MDA-MB-231 cells were transfected with siRNA to AMPKα1,
AMPKα2, Akt1, or p110α alone or in combinations. Transfection concentrations
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM
total), and (3) siNTC: 100 nM. Cells were plated at a density of 3,000 cells/well
48h after transfection. SRB growth assay was performed 48h after plating (n =
12). *indicates p-value < 0.0001; NTC, Non-targeting control was used as a
negative control.
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Figure 3.7 Radiation increases levels of activated and total AMPKα in MDAMB-231 cells.
(A) MDA-MB-231 cells were exposed to 0, 2, 4, or 6 Gy radiation dose and
collected 1h after irradiation. Total and phosphorylated AMPKα and DNA-PKcs
expression levels were determined by Western blot. (B) MDA-MB-231 cells were
exposed to 0 or 6 Gy radiation dose and collected 1h, 2h, 4h, or 24h after
irradiation. Total and phosphorylated AMPKα and DNA-PKcs expression levels
were determined by Western blot.
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Figure 3.8 Knockdown of Akt1 potentiates radiation-induced apoptosis in
MDA-MB-231 cells.
(A) MDA-MB-231 cells were exposed to 0, 6, or 10 Gy radiation dose and
collected 48h or 72h after irradiation. Expression of cleaved PARP and cleaved
caspase-3 was determined by Western blot. (B) MDA-MB-231 cells were
exposed to 0, 2, 4, or 6 Gy radiation dose daily for 4d and collected 24h after the
last radiation treatment. Expression of cleaved PARP and cleaved caspase-3
was determined by Western blot. (C) MDA-MB-231 cells were transfected with
siRNA to AMPKα1, Akt1, or AMPKα1/Akt1. Transfection concentrations were: (1)
individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM total), and
(3) NTC: 100 nM. Cells were exposed to 0 or 6 Gy radiation dose 24h after
transfection and collected 48h after radiation. Expression of AMPKα1, Akt1, and
cleaved PARP was determined by Western blot. (D) MDA-MB-231 cells were
exposed to 0 or 4 Gy radiation dose and then transfected with siRNA to
AMPKα1, Akt1, or AMPKα1/Akt1 on the same day. Transfection concentrations
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM
total), and (3) NTC: 100 nM. Cells were collected 72h after transfection.
Expression of AMPKα1, Akt1, and cleaved PARP was determined by Western
blot. (E) MDA-MB-231 cells were exposed to 0 or 4 Gy radiation dose and then
incubated for 48h. Cells were then treated with 0 or 10 μM of A-674563 or MK2206 for 24h. Expression of pAkt, Akt1, and cleaved PARP was determined by
western blot. (F) MDA-MB-231 cells were exposed to 0 or 4 Gy radiation dose
and then incubated for 48h. Cells were then treated with 0 or 10 μM of AZD5363
or Perifosine for 24h. Expression of pAkt, Akt1, and cleaved PARP was
determined by western blot. (G) Summary diagram showing Akt1 inhibition and
radiation-induced apoptosis in TNBC cells. For A-D, NTC (Non-targeting control)
was used as a negative control.
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Figure 3.9 Silencing Akt1 enhances radiation-induced apoptosis in MDAMB-231 cells.
(A) MDA-MB-231 cells were transfected with siRNA to AMPKα1, Akt1, or
AMPKα1/Akt1. Transfection concentrations were: (1) individual siRNA: 50 nM, (2)
combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM. Cells were
exposed to 0 or 6 Gy radiation dose 24h after transfection and collected 48h after
radiation. Expression of AMPKα1, Akt1, and cleaved PARP was determined by
western blot. (B) MDA-MB-231 cells were transfected with siRNA to AMPKα1,
Akt1, or AMPKα1/Akt1. Transfection concentrations were: (1) individual siRNA:
50 nM, (2) combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM.
Cells were seeded at a density of 100 cells/well into 96-well plates 48h after
transfection. Cells were exposed to 0 or 4 Gy radiation dose 24h later. Colonies
were fixed and quantified with the SRB assay protocol 1 week after irradiation (n
= 18). NTC, Non-targeting control was used as a negative control. *indicates p <
0.01 vs. group control; † indicates p < 0.0001 vs. no radiation.
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CHAPTER 4: ROLE OF AKT AND AMPK IN TRIPLE NEGATIVE BREAST
CANCER LUNG METASTASIS
4.1 Abstract
Triple negative breast cancer (TNBC) is a very aggressive disease with a
5-year relative survival rate of 11% after distant metastasis. Organ metastasis
imposes stressful conditions on cells, which adapt by increasing energy
production and upregulating survival pathways. AMP-activated protein kinase
(AMPK) and Akt control energy levels and survival; however, their role during
early-stage metastasis is unknown. The purpose of this study was to establish
whether targeting both Akt and AMPKα in circulating cancer cells suppresses
TNBC early-stage lung colonization. Silencing Akt1 or Akt2 dramatically
decreased lung metastasis establishment in lungs by inducing apoptosis or
inhibiting invasion, respectively. Allosteric inhibition of Akt activity with MK-2206
did not reduce TNBC lung metastasis. Knockdown of AMPKα1, AMPKα2, or
AMPKα1/2 did not suppress metastatic colonization of lungs. Taken together,
these findings demonstrate that metabolic pathways regulated by AMPK isoforms
are not essential for circulating TNBC tumor cells survival or metastatic lung
colonization. However, we identify Akt1 or Akt2 expression as key mediators of
lung colonization that may serve as potential targets to prevent metastatic spread
and improve survival among TNBC patients.
4.2 Introduction
Breast cancer is the second leading cause of cancer death among women
globally, and projections estimate that there will be over 42,000 deaths in the
United States in 2020 [1]. Most deaths are due to metastatic spread of the cancer
to the lungs, brain, or bone [2]. Triple negative breast cancer (TNBC) is an
aggressive subtype of breast cancer that comprises 15-20% of overall cases [35, 7, 9]. TNBC, characterized by a lack of expression of the estrogen and
progesterone receptors and no overexpression of the HER2 protein, consists of a
diverse group of tumors that affect younger women and are found with greater
frequency in African Americans [6, 7, 9, 124]. TNBC has proven resistant to
targeted therapy and is more likely to recur and metastasize to distant organs [6,
7, 9, 124]. The lungs are the primary site of TNBC colonization with
approximately 40% of TNBC metastases occurring in the lungs [125]. The
survival rate for TNBC significantly decreases once it has metastasized to
systemic organs [37]. The 5-year relative survival rate of localized TNBC is 91%
and 65% with regional metastasis; however, survival precipitously drops to 11%
with distant spread [37]. TNBC patients with lung metastases have a median
survival of only 15 months [126]. Understanding the mechanism of TNBC
metastatic spread to lungs and preventing the establishment of micrometastases
in distant organs will directly improve patient survival.
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Metastasis is a multistep process that requires cells to follow five
sequential steps: infiltrate surrounding tissue, intravasate into a blood or
lymphatic vessel, survive during transit, extravasate into an organ, and proliferate
to form colonies [127]. Cells must become motile before infiltrating surrounding
tissue, and they undergo the epithelial-to-mesenchymal transition (EMT) to
increase migratory ability [127]. Once in a vessel, cells travel and must survive
until they lodge in capillaries or adhere to endothelial cells of the vessel wall
[128]. Cells then extravasate into surrounding tissue within a few hours [128].
After arriving at a distant site, metastatic cells rely on oncogenes to promote
survival [128]. Only a subset of surviving cells proliferates to form a colony [128].
Metastasis is extremely inefficient with less than 0.1% of cells surviving at distant
sites [127]. Survival during transport and extravasation into an organ are key
steps in early-stage metastasis that can be targeted to prevent the establishment
of colonies at distant sites. Since metastasis to distant organs happens in a
short-time frame, we decided to identify the role of key survival or metabolism
proteins by regulating their expression in circulating cancer cells. This model
focuses specifically on the fate of cancer cells after intravasation but before
proliferation of micrometastases.
During organ metastasis, cells rely on increased energy production and
oncogene expression to adapt to stressful conditions [128, 129]. Inhibiting
pathways that help cells alter metabolism or overcome stresses during earlystage metastasis may reduce their ability to successfully metastasize. Akt and
AMP-activated protein kinase (AMPK) are two proteins that play crucial roles in
cellular survival and metabolism, respectively. Moreover, Akt and AMPK
reciprocally regulate each other during matrix attachment and detachment in
breast cancer [115]. Akt promotes growth of matrix-attached cells, while AMPK
increases energy availability for matrix-detached cells [115]. Concurrently
targeting signaling through Akt and AMPK may synergistically reduce the ability
of TNBC to metastasize.
Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is
composed of three isoforms: Akt1, Akt2, and Akt3 [92-95, 116, 130]. Akt
promotes cellular growth and survival by phosphorylating and regulating many
targets, including the mammalian target of rapamycin (mTOR) [92-95, 116, 130].
The ability of Akt1 and Akt2 to control metastasis of estrogen receptor-positive
(ER+) and HER2-amplied breast cancers has previously been studied. Akt1
inhibits metastasis of both breast cancer subtypes, while Akt2 has a prometastatic role in both cases [104-106]. However, the impact of Akt1 and Akt2 on
TNBC metastasis is unknown. AMPK is a heterotrimeric complex that is
composed of an α catalytic subunit and β and γ regulatory subunits [44, 46-48,
53]. The catalytic domain is comprised of α1 and α2 isoforms [44, 46-48, 53].
AMPK is a major metabolic regulator that maintains energy homeostasis of cells
by increasing ATP production and reducing ATP consumption [44, 46-48, 53]. In
particular, AMPK reduces lipid synthesis and stimulates fatty acid oxidation by
phosphorylating acetyl CoA carboxylase [44, 47, 48, 53]. Both fatty acid
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synthesis and oxidation can promote metastasis [89]. AMPK may play a key role
in balancing flux through these pathways during different stages of metastasis.
However, the specific steps of TNBC metastasis that are regulated by AMPKα1
and AMPKα2 is unclear. Moreover, combined targeting of individual Akt and
AMPKα isoforms to reduce TNBC metastasis has not been previously examined.
Here, we determined how Akt and AMPKα isoforms affect the early-stage
metastatic potential of TNBC cells and whether combined inhibition can
synergistically block metastasis in vivo. We found that silencing either Akt1 or
Akt2 dramatically decreased lung colonization of TNBC cells by inducing
apoptosis or inhibiting invasion, respectively. The reductions in metastasis were
independent of Akt activation. Knockdown of AMPKα1, AMPKα2, or AMPKα1/2
did not prevent lung metastasis or synergistically suppress lung colonization
when combined with Akt isoform knockdown. Taken together, our findings
establish Akt1 and Akt2 as key mediators of TNBC lung colonization.
Suppressing Akt1 or Akt2 expression may directly decrease mortality in TNBC
patients.
4.3 Materials and methods
4.3.1 Materials
Roswell Park Memorial Institute (RPMI) 1640 medium was from Thermo
Fisher (Waltham, MA). DMEM/F12 was from Sigma-Aldrich (St. Louis, MO). Fetal
bovine serum (FBS), 100x penicillin-streptomycin solution (PS), and Dulbecco’s
Phosphate Buffered Saline (PBS) were from Sigma-Aldrich. Opti-MEM and
Lipofectamine RNAiMAX were from Thermo Fisher. Protein Assay Dye was from
Bio-Rad (Hercules, CA). Amersham ECL Prime Western Blotting Detection
Reagent was from GE Healthcare Life Sciences (Chicago, IL). Immobilon
Western Chemiluminescent HRP Substrate was from Millipore (Burlington, MA).
Pooled siRNAs for AMPKα1, AMPKα2, and AMPKα1/2 were from Santa Cruz
Biotechnology (Dallas, TX). Pooled siRNAs for Akt1 and Akt2 were from Thermo
Fisher. MISSION pLKO.1-puro-CMV-TurboGFP Positive Control Transduction
Particles (Sigma-Millipore; #SHC003V) were used to establish MDA-MB-231
green fluorescent protein (GFP) cells. MK-2206 2HCl was from Cayman
Chemical (Ann Arbor, MI). Primary antibodies used in this study include: Abcam:
(1) AMPKα1, ab32047 (1:1000 for WB and 1:250 for IHC) and (2) AMPKα2,
ab3760 (1:1000 for WB and 1:500 for IHC); Cell Signaling Technology (Danvers,
MA): (1) pAkt, #4060 (1:2000 for WB), (2) Akt1, #75692 (1:1000 for WB), (3)
Akt2, #3063 (1:1000 for WB), (4) Cleaved PARP, #5625 (1:1000 for WB), (5) ZO1, #8193 (1:1000 for WB), (6) ZEB1, #3396 (1:1000 for WB), (7) Claudin-1,
#13255 (1:1000 for WB), (8) E-cadherin, #3195 (1:1000 for WB), (9) Vimentin,
#5741 (1:1000 for WB), (10) β-catenin, #8480 (1:1000 for WB), (11) Snail, #3879
(1:1000 for WB), (12) Bcl-2, #4223 (1:1000 for WB), (13) Bcl-xL, #2764 (1:1000
for WB), (14) Mcl-1, #5453 (1:1000 for WB), (15) Bim, #2933 (1:1000 for WB),
(16) Bad, #9239 (1:1000 for WB), and (17) BID, #2202 (1:1000 for WB); and
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Sigma-Aldrich: β-actin (1:10,000 for WB). Akt1, #sc-5298 (1:500 for IHC), Akt2,
#sc-5270 (1:500 for IHC), and secondary antibodies were from Santa Cruz
Biotechnology.
4.3.2 Cell Culture
TNBC cells (MDA-MB-231 and MDA-MB-468 cells) were from the
American Type Culture Collection and cultured in a humidified incubator at 37°C
and 5% CO2. MDA-MB-231 cells were cultured in RPMI + 10% FBS + 1% PS.
MDA-MB-468 cells were cultured in DMEM/F12 + 10% FBS + 1% PS. To
generate MDA-MB-231 GFP cell line, 5,000 cells were seeded into a 96-well
plate and incubated at standard cell culture conditions overnight. On the following
day, cells were transfected with GFP lentiviral particles (MOI = 40) in medium
supplemented with 10 μg/ml polybrene. The medium was changed after 24h, and
cells were seeded 24h later into a 24-well plate. The cells were selected the next
day with 1 μg/mL of puromycin.
4.3.3 siRNA Transfection
TNBC cells were transfected with 50 nM of siRNA to NTC, Akt1, Akt2,
AMPKα1, AMPKα2, or AMPKα1/2. The siRNAs were mixed with Lipofectamine
RNAiMAX in Opti-MEM for 20 min. The ratio of Opti-MEM to complete medium
was 1:4. Medium was changed every 24h until cells were injected into mice or
lysed for western blotting.
4.3.4 Western blotting
TNBC cells were seeded and then transfected as described above.
Medium was changed after 24h and again after 48h. After incubation for a total of
72h, medium was removed, and cells were washed with ice cold 1x PBS. Cells
were then scraped and lysed in 1x radioimmunoprecipitation assay (RIPA) buffer
containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were incubated on
ice for 20 min with 10-sec vortexes every 5 min before centrifugation at 14,000
rpm for 20 min at 4°C. Protein concentrations in the lysates were then
determined. Equal amounts of protein were reduced and denatured by heating at
80°C for 10 min before being resolved on 4-12% Bis-Tris gels. The proteins were
then transferred to polyvinylidene fluoride (PVDF) membranes, blocked with 10%
milk for at least 1h, and incubated in primary antibody solutions overnight at 4°C.
On the next day, the membranes were washed twice with 1x Tris-buffered saline
with Tween 20 (TBST) for 5 min and 10 min before incubation with secondary
antibody solutions (1:10,000 dilutions) for 1h at room temperature. The
membranes were then washed twice with TBST for 15 min and 20 min before
Amersham ECL or Immobilon was added to the membranes for protein detection.
Stripping buffer was used on membranes where required.
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4.3.5 Immunohistochemistry
Samples of TNBC lymph node metastases were identified by the Markey
Cancer Center Biospecimen Procurement and Translational Pathology shared
resource facility. Immunohistochemistry (IHC) was performed as previously
described [131]. Briefly, slides were deparaffinized in xylene, rehydrated,
incubated for 15 min with fresh 0.3% hydrogen peroxide, washed with PBS, and
heated to 95°C in 10 mM citrate buffer (pH 6.0; 30 min) for Akt1 and Akt2
antibody staining. Antigen retrieval for slides stained with AMPKα1 and AMPKα2
antibody was performed in Diva Decloaker, RTU (Biocare Medical; # DV2004G1)
buffer. Antigen retrieval for sliders stained with Akt1 and Akt2 were performed in
sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0).
Endogenous peroxidase activity was blocked with Bloxall blocking solution
(Vector Laboratories; # SP-6000). Next, sections were blocked for 1h with 2.5%
normal horse serum (Vector Laboratories; #S-2012). AMPKα1, AMPKα2, Akt1,
and Akt2 antibodies were diluted in Dako background reducing antibody diluent
(Agilent Dako; #s3022). Primary antibody was incubated with slides for 12 h at
4°C in a humidifier chamber, washed with TBST (Tris-Buffered Saline and Tween
20) and incubated with ImmPRESS universal antibody IgG polymer detection kit
(Vector Laboratories, #MP-7500) for 1h, RT. Antibody reaction was visualized
with Immpact DAB EqV peroxidase substrate (Vector Laboratories, #SK-4103).
All sections were counterstained with hematoxylin (VWR; #95057-844) and
observed by light microscopy. For negative controls, primary antibody was
omitted from the above protocol.
The number of positive cells was visually evaluated in each core by a
pathologist, and the staining intensity was classified using a semi-quantitative
seven-tier system developed by Allred et al. [132, 133]. The system assesses the
percentage of positive cells (none=0; <10%=1; 10% to 50%, =2; >50%=3) and
intensity of staining (none=0; weak=1; intermediate=2; and strong=3).
4.3.6 TNBC lung metastasis model
NOD-scid IL2Rgammanull mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Housing for these animals was maintained in a
HEPA-filtrated environment within sterilized cages with 12 h light/12 h dark
cycles. All animal procedures were conducted with approval of and in compliance
with the University of Kentucky Institutional Animal Care and Use Committee.
Knockdown of Akt and AMPK isoforms in circulating cancer cells was
achieved by transient knockdown of protein expression in vitro, as described
above, and injection of cancer cells intravenously (iv) into mice 48h after
transfection. Briefly, cells were washed with 1x PBS 48h after transfection,
trypsinized, counted and resuspended in PBS at a density of 1 x 10 6 cells per
100 μL. Cells were kept on ice before intravenous injection. For iv injection of
MDA-MB-231 GFP cells, NOD-scid IL2Rgammanull mice were anesthetized with
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isoflurane (induction 4%, maintenance 2%). The viability of cells used for
inoculation was greater than 95% as determined by Vi-CELL™ XR (Beckman
Coulter); 1x106 cells were injected per animal. Gentle pressure was applied to
the inoculation site until there was no visible sign of bleeding. GFP fluorescence
imaging was performed using an LT-9500 Illumatool/TLS (Lightools Research,
Encinitas, CA), equipped with an excitation source (470 nm) and filter plate (515
nm).
4.3.7 MK-2206 in vivo experiment
GFP-expressing MDA-MB-231 cells were treated with MK-2206 (0 or 10
μM). After 22h, medium was replaced with fresh medium containing MK-2206 (0
or 10 μM) for an additional 2h. Akt activity is suppressed with MK-2206 treatment
for 2h, so treatment was renewed for the final 2h to ensure that pAkt inhibition
was maintained [134, 135]. Cells were then collected and counted before iv
injection into the tail vein of mice.
4.3.8 Analysis of GFP signal in TNBC lung metastases
ImageJ software was used to evaluate GFP signal in TNBC lung
metastases. ImageJ is a Java-based image processing program developed at
the National Institutes of Health and the Laboratory for Optical and
Computational Instrumentation (LOCI, University of Wisconsin;
https://imagej.nih.gov/). Photographs of lung metastases were opened in ImageJ
software and split into channels (Image-Color-Split Channels). Blue and red
channels were closed, and the green channel was adjusted with threshold
function (Image-Adjust-Threshold; select B&W in drop-down menu). Next, a
rectangular selection area was drawn over a lung to perform measurement of
mean gray values. Analysis properties were set to “area” and “Mean grey value”
(Analyze-Set Measurement). Mean grey values in the rectangular selection area
drawn over a lung were analyzed and recorded (Analyze-Measure). To keep the
area of selection consistent, the rectangular selection area was moved over the
next lung and the analysis was repeated (Analyze-Measure).
4.3.9 Statistical analysis
Descriptive statistics, including means and standard deviations (SD), are
presented for each experimental group and displayed in bar graphs while
frequencies and proportions of IHC score were summarized for Akt and AMPK.
Comparisons of green fluorescence area were performed using the one-way
analysis of variance (ANOVA) with Holm’s adjustment for multiple testing
between groups. The chi-square test for goodness of fit was used to test
departures from equality of proportions across IHC scores. p<0.05 was
considered to indicate a statistically significant difference. Statistical analyses
were performed using SAS software version 9.4 (SAS Inc., Cary, NC, USA).
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4.4 Results
4.4.1 Expression of Akt and AMPKα isoforms in TNBC lymph node metastases
Akt and AMPKα promote cellular survival and energy mobilization and
may facilitate organ colonization during metastatic spread [60, 62, 92, 115, 122,
123, 136]. We have previously shown that AMPKα1 and AMPKα2 are expressed
in TNBC patient samples [137]. However, the expression of Akt and AMPKα
isoforms in TNBC distant metastases is unclear. Therefore, we determined the
expression and subcellular localization of Akt1, Akt2, AMPKα1, and AMPKα2 in
45 TNBC lymph node metastases. Figure 4.1A-D indicates the cytoplasmic
scoring distribution and representative staining for each isoform in the TNBC
patient samples. Akt1, Akt2, and AMPKα1 received scores of 5 or 6 in over 70%
of cases, indicating intense and widespread cytoplasmic expression among the
lymph node metastases (Figure 4.1A-C). Chi-square tests indicated statistically
significant higher IHC scores for Akt1, Akt2, and AMPKα1. Figures 4.2, 4.3, and
4.4 contain all IHC staining images for Akt1, Akt2, and AMPKα1. AMPKα2 had
slightly lower scores than the other proteins, with over 80% of samples being
scored as a 4 or 5 (Figure 4.1D). Moreover, AMPKα2 was not expressed in the
cytoplasm in 11% of cases. These findings suggest that cytoplasmic expression
of AMPKα2 is moderately strong and widespread among the patient samples.
Chi-square tests also indicated statistically significant higher IHC scores for
AMPKα2. Figure 4.5 contains all IHC staining images for AMPKα2. Taken
together, these results suggest that Akt1, Akt2, AMPKα1, and AMPKα2 may play
important roles in facilitating TNBC metastasis to distant sites.
Figure 4.1E compares the subcellular localization of Akt1, Akt2, AMPKα1,
and AMPKα2 within the TNBC lymph node metastases. In most samples, Akt1,
Akt2, and AMPKα1 were expressed in only the cytoplasm. Akt1, Akt2, and
AMPKα1 were found in both the nucleus and cytoplasm in a minority of cases,
but no samples contained only nuclear expression. AMPKα2 had a substantially
different subcellular localization pattern than Akt1, Akt2, or AMPKα1. AMPKα2
was expressed in both the nucleus and the cytoplasm in a majority of samples. In
addition, AMPKα2 was expressed in only the cytoplasm in 4 samples. This
analysis suggests that AMPKα2 is preferentially localized in the nucleus
compared to AMPKα1 or Akt isoforms. Taken together, these findings indicate
that Akt1, Akt2, and AMPKα1 are predominantly expressed in the cytoplasm of
TNBC lymph node metastases while AMPKα2 is found in both the nucleus and
cytoplasm.
4.4.2 Role of Akt and AMPKα isoform expression on proteins that regulate
apoptosis induction and invasion in TNBC cells
Survival during transport and extravasation through the vessel wall are
essential steps for cells to establish distant metastases [127, 128]. Therefore,
proteins that prevent apoptosis induction or facilitate invasion may play a major
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role in promoting TNBC lung colonization. Akt1 regulates apoptosis induction in
MDA-MB-231 cells, but the ability of Akt2 and AMPKα isoforms to control
apoptosis in TNBC cells is unclear [136]. Moreover, the effect of Akt or AMPKα
isoforms on many invasion-promoting proteins in TNBC cells is unknown.
We next determined the differential expression of invasive proteins in
TNBC cells after knockdown of Akt and AMPKα isoforms. Using siRNA
transfection, levels of Akt1, Akt2, AMPKα1, or AMPKα2 were depleted in MDAMB-231 and MDA-MB-468 cells (Figure 4.6). As shown in Figure 4.6A,
knockdown of Akt2 decreased expression of Snail and Claudin-1 in MDA-MB-231
and MDA-MB-468 cells. Silencing Akt1 did not consistently affect expression
levels of various invasive proteins in MDA-MB-231 and MDA-MB-468 cells
(Figure 4.6A). Similarly, knockdown of AMPKα1 or AMPKα2 did not consistently
impact expression of invasive proteins in our panel of TNBC cells (Figure 4.6B).
Taken together, these findings indicate that Akt2 regulates expression of proteins
that may promote extravasation in circulating TNBC cells.
Next we determined whether Akt and AMPKα isoforms control apoptosis
induction in TNBC cells. siRNA transfection was used to diminish expression of
Akt1, Akt2, AMPKα1, or AMPKα2 in MDA-MB-231 and MDA-MB-468 cells
(Figure 4.7). As shown in Figure 4.7A, Akt1 knockdown induced PARP cleavage
in both MDA-MB-231 and MDA-MB-468 cells. Silencing Akt2 also led to robust
PARP cleavage in MDA-MB-468 cells. Neither AMPKα1 nor AMPKα2 knockdown
induced PARP cleavage in MDA-MB-231 cells (Figure 4.7B). These findings
suggest that either Akt1 or Akt2 knockdown promotes apoptosis induction in
TNBC cells. We then determined how silencing Akt1 or Akt2 impacted
expression of Bcl2 family proteins, which regulate apoptosis induction. Akt1
knockdown increased the expression of Bim, a promoter of apoptosis, in MDAMB-231 and MDA-MB-468 cells (Figure 4.7C). Silencing Akt2 reduced levels of
Mcl-1, an anti-apoptotic protein, in both MDA-MB-231 and MDA-MB-468 cells
(Figure 4.7C). Taken together, these findings indicate that Akt1 and Akt2 prevent
apoptosis in TNBC cells by reducing Bim expression or upregulating Mcl-1 levels,
respectively.
4.4.3 Akt1 and Akt2 promote lung colonization of circulating MDA-MB-231 cells
The ability of individual Akt and AMPKα isoforms to regulate TNBC lung
colonization is unknown. Moreover, the effect of combined inhibition of Akt and
AMPKα isoforms on lung colonization of circulating TNBC cells is unclear.
Therefore, we determined how silencing Akt1, Akt2, AMPKα1, AMPKα2, or
AMPKα1/2—alone or in combination—affects lung colonization of MDA-MB-231
cells. We selected a transient transfection model to examine lung colonization of
TNBC cells. Transfection with siRNA leads to cleavage and subsequent
degradation of the targeted mRNA sequence [138, 139]. As a result, the mRNA
cannot be translated into the amino acid residues that comprise the protein of
interest. Once the existing cellular proteins are degraded, the siRNA-induced
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decreases are apparent. Robust decreases in target protein levels in Figs 2 and
3 were observed at 72h after transfection. Therefore, transfected cells were
prepared for injection into mice to ensure that maximum knockdown in protein
expression was present while the cells were in circulation. As a result,
knockdown would impact survival during transport or extravasation into lung
parenchyma, but it would not affect steps after invasion—such as colony
formation and proliferation. Thus, this model allows us to establish whether Akt
and AMPKα isoforms affect the ability of circulating TNBC cells to colonize lungs.
First, siRNA transfection was used to generate transient knockdown of
Akt1 or Akt2 in GFP-expressing MDA-MB-231 cells, which were injected into the
tail vein of mice after 48h. Figure 4.8A indicates that knockdown of either Akt1 or
Akt2 dramatically decreased MDA-MB-231 invasion into lung parenchyma.
Silencing Akt1 or Akt2 blocked metastasis to a similar degree. Quantification of
green fluorescence intensity with ImageJ indicated that both reductions were
statistically significant (Figure 4.8B). Taken together, these results suggest that
Akt1 and Akt2 promote lung colonization of circulating TNBC cells.
Next, we determined how combined inhibition of AMPKα1 and Akt1
affected apoptosis induction and lung colonization in MDA-MB-231 cells.
Depleting Akt1 levels induced PARP cleavage and increased Bim expression,
but combined knockdown with AMPKα1 did not enhance either effect (Figure
4.9A). We then reduced expression of AMPKα1 and Akt1 alone or in combination
in GFP-expressing MDA-MB-231 cells before injecting into mice. As shown in
Figure 4.9B, silencing AMPKα1 did not affect the ability of cells to invade into
murine lungs. Suppressing Akt1 expression prevented MDA-MB-231 lung
metastasis, which is consistent with the finding from Figure 4.8. However,
combined knockdown of AMPKα1 and Akt1 did not inhibit metastasis more than
silencing Akt1 alone. We next depleted levels of AMPKα2 in GFP-expressing
MDA-MB-231 cells and injected into mice. As noted in Figure 4.9C, AMPKα2
knockdown did not affect metastatic spread of MDA-MB-231 cells to the lungs.
Since neither AMPKα1 nor AMPKα2 alone impacted lung colonization of MDAMB-231 cells, we then examined how AMPKα1/2 affects lung metastasis. We
suppressed expression of AMPKα1/2 in GFP-expressing MDA-MB-231 cells
before injecting into mice. As shown in Figure 4.9D, silencing AMPKα1/2 did not
impact the ability of MDA-MB-231 cells to invade into lung parenchyma. Taken
together, these findings indicate that Akt1 and Akt2 facilitate lung colonization of
circulating TNBC cells while AMPKα does not impact TNBC lung colonization.
4.4.4 Akt1 and Akt2 promote TNBC lung colonization independent of Akt activity
We showed that silencing Akt1 or Akt2 dramatically decreased lung
colonization of circulating MDA-MB-231 cells. However, our prior experiments did
not establish whether this effect was due to (1) reduced Akt activity secondary to
knockdown, or (2) decreased expression of Akt1 and Akt2. To address this
question, we suppressed Akt activity in MDA-MB-231 cells with MK-2206, an
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allosteric Akt inhibitor, prior to iv cell injection. As shown in Figure 4.10A, we
confirmed that MK-2206 treatment reduced Akt activity in MDA-MB-231 cells.
Figures 4.10B and 4.10C indicate that inhibiting Akt activity did not affect MDAMB-231 lung colonization. Taken together, these findings suggest that the ability
of Akt1 and Akt2 to promote lung colonization of circulating TNBC cells is
independent of Akt activity. Reducing metastatic potential of TNBC by
suppressing Akt1 and/or Akt2 expression is a potentially promising therapeutic
strategy that may directly improve patient survival.
4.5 Discussion
Preventing metastatic spread of TNBC is crucial to improving patient
survival. Akt and AMPK are two key proteins that serve vital functions for cancer
cells during stress. The Akt signaling cascade promotes cellular survival by
inhibiting apoptosis and facilitates cellular growth by stimulating cell cycle
progression. AMPK is an important regulator of metabolism and helps cells
maintain energy homeostasis in times of stress. Moreover, Akt and AMPK
reciprocally regulate each other during matrix attachment and detachment in
breast cancer [115]. The existence of this reciprocal regulatory loop prompted
our interest in targeting both pathways together to block metastasis. We
hypothesized that combined inhibition of Akt and AMPK would prevent TNBC
lung colonization more than targeting either pathway alone, thereby improving
patient survival.
Mutations that activate the PI3K/Akt/mTOR pathway are frequently found
in breast cancer [140]. However, the ability of individual Akt isoforms to mediate
metastasis of TNBC cells is not well understood. We found that silencing Akt1
dramatically decreased lung colonization of circulating TNBC cells and induced
PARP cleavage and Bim expression. Prior work has found that Akt1 maintains
the viability of tumor-initiating cells by reducing Bim expression [136]. Therefore,
our results indicate that Akt1 may support lung metastasis of circulating TNBC
cells by preventing apoptosis induction. To our knowledge, this is the first study
to establish that Akt1 expression promotes the in vivo metastatic potential of
TNBC cells. Previous work has found that Akt1 blocks metastasis of other breast
cancer subtypes [104-106]. Akt1 inhibits invasion of ER+ breast cancer cells, and
Akt1 overexpression attenuates HER2-mediated metastasis of murine mammary
tumors [104-106]. TNBC is a very aggressive disease that is 4x more likely to
metastasize to viscera than non-TNBCs within the first 5 years [141]. Therefore,
TNBC metastasis may be promoted by proteins that do not facilitate spread of
other cancers. Our findings suggest that Akt1 is a key regulator of lung
colonization in TNBC cells.
Akt2 is more frequently amplified in cancer cells than Akt1, but its ability to
regulate TNBC lung colonization is also unknown [92]. We found that silencing
Akt2 significantly reduced TNBC lung colonization and suppressed expression of
Snail, Claudin-1, and the anti-apoptotic protein Mcl-1. Claudin-1 promotes the
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invasive potential of nasopharyngeal carcinoma cells, and Snail is required for
TNBC cells to invade into lymph nodes [142, 143]. Therefore, our findings
suggest that Akt2 may promote lung metastasis of circulating TNBC cells two
ways: (1) facilitating extravasation through the vessel wall and into lung
parenchyma and (2) preventing apoptosis induction. To our knowledge, this is
the first study to identify Akt2 as a key mediator of lung colonization in circulating
TNBC cells. Prior work has indicated that Akt2 facilitates metastasis of other
breast cancer subtypes [105, 106]. Akt2 promotes the migration and invasion of
ER+ breast cancer cells, and Akt2 overexpression increases HER2-mediated
metastasis of murine mammary tumors [105, 106]. Our findings suggest that Akt2
is also an important regulator of metastasis in TNBC cells.
Akt1 and Akt2 facilitate TNBC lung colonization independent of Akt
activity. We showed that silencing Akt1 or Akt2 does not correlate with a
substantial reduction in pAkt expression. This is most likely due to compensatory
phosphorylation of the isoform that is still present within the cells. Despite a
corresponding reduction in pAkt levels, knockdown of Akt1 or Akt2 significantly
suppressed TNBC metastasis. Other studies have also found a non-kinase
function for Akt [144, 145]. Akt1 has been shown to reduce toll-like receptor
signaling in a kinase-independent fashion [144]. Moreover, Akt promotes cell
survival in a kinase-independent manner and instead relies on its pleckstrin
homology domain [145]. Akt1 and Akt2 may facilitate survival of circulating TNBC
cells in a similar manner, but further work is needed to establish the underlying
mechanisms. A prior study has found that overexpression of pAkt is correlated
with an increased rate of brain metastasis in lung cancer patients [146]. Our
findings suggest that the role of pAkt may vary between cancer types or that pAkt
mainly stimulates growth of cells that have already colonized distant organs.
Suppressing Akt1 and/or Akt2 expression is a novel therapeutic strategy
that could be implemented for TNBC patients who are resistant to current
therapeutic regimens. Our findings indicate that pharmacological reduction of
Akt1 and/or Akt2 expression in TNBC patients with refractory tumors may
prevent metastatic spread, thereby directly improving survival. Current clinical
trials are focused on developing Akt inhibitors as therapeutic agents for breast
cancer patients. However, we suggest that future studies should identify agents
that can decrease Akt1 and/or Akt2 expression and evaluate their ability to limit
metastasis of non-responsive TNBC.
In addition to Akt1 and Akt2, we also studied how AMPKα isoforms impact
lung colonization. AMPKα is a major metabolic regulator that may balance
energy demand during different stages of metastasis. When cells detach from a
matrix, they are unable to import glucose and instead must increase ATP
synthesis through other pathways [88]. AMPKα’s ability to mobilize energy via
different metabolic pathways suggests that it may have an important role in
restoring energy homeostasis for circulating cells. Moreover, fatty acid synthesis
and oxidation—both of which are regulated by AMPKα—have been reported to
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promote metastasis [89]. Prior studies have found that AMPKα affects TNBC
metastasis in an isoform-dependent fashion. AMPKα1 prevents metastatic
spread of TNBC cells, while AMPKα2 promotes metastasis of TNBC cells [90,
91]. However, the specific stages of metastasis that are controlled by AMPKα1
and AMPKα2 in TNBC cells is unclear. In addition, combined inhibition of Akt and
AMPKα isoforms has not been studied. We found that transiently silencing
AMPKα1, AMPKα2, or AMPKα1/2 alone did not affect lung colonization of
circulating MDA-MB-231 cells. Moreover, AMPKα knockdown did not
synergistically block TNBC lung metastasis when combined with Akt isoform
knockdown. These findings suggest that AMPKα1, AMPKα2, and AMPKα1/2 do
not impact lung colonization of circulating MDA-MB-231 cells.
Our findings expand on these prior studies, which used stable knockdown
or overexpression cells instead of transiently transfected cells [90, 91]. Unlike our
experimental design, stable cell lines will not lose knockdown or overexpression
after extravasation into tissue. As a result, previous work has not delineated
whether AMPKα isoforms regulate metastasis of circulating TNBC cells or
regulate proliferation of established microcolonies. Our study is able to
differentiate metastatic stages that precede lung colonization from those that
follow lung colonization. Our findings indicate that neither AMPKα1 nor AMPKα2
impact survival or extravasation of circulating TNBC cells. However, AMPKα has
been shown to affect TNBC cell growth [60, 62, 137]. We have previously
reported that AMPKα1 and AMPKα2 promote cell cycle progression and
proliferation in TNBC cells [137]. Moreover, pharmacological activators of
AMPKα have also reduced growth and cell cycle progression of TNBC cells [67,
73, 147]. Therefore, the major effect of AMPKα isoforms on TNBC metastasis
may involve growth regulation of cells that have already survived during transport
and extravasated into tissue.
In summary (Figure 4.10D), we have shown that reducing Akt1 or Akt2
expression prevents lung colonization of TNBC cells. Akt1 facilitates lung
metastasis by inhibiting apoptosis induction, while Akt2 promotes lung metastasis
by enabling extravasation through the vessel wall and into surrounding tissue.
These reductions in metastasis are independent of Akt activity. Silencing
AMPKα1, AMPKα2, or AMPKα1/2 does not reduce lung colonization or
synergistically block lung metastasis when combined with Akt isoform
knockdown. Importantly, suppressing Akt1 and/or Akt2 expression is a potentially
promising therapeutic strategy that could reduce lung colonization and thus
decrease mortality among TNBC patients.
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Figure 4.1 Akt1, Akt2, AMPKα1, and AMPKα2 expression in TNBC lymph
node metastases.
Analysis of (A) Akt1, (B) Akt2, (C) AMPKα1, and (D) AMPKα2 expression in the
cytoplasm of TNBC lymph node metastases. Samples were scored on scales of
0-3 for both intensity and distribution percentage, and the values were added
together (n = 45). Representative IHC staining for each protein is demonstrated
below each pie chart. (E) Distribution of Akt1, Akt2, AMPKα1, and AMPKα2
cytonuclear localization in TNBC lymph node metastases (n = 45; * indicates
p<0.0001).
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Figure 4.2 Akt1 is expressed in TNBC lymph node metastases.
IHC staining of Akt1 in TNBC lymph node metastases. Samples were scored on
scales of 0-3 for both intensity and distribution percentage and then added
together (n = 45).
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Figure 4.3 Akt2 is expressed in TNBC lymph node metastases.
IHC staining of Akt2 in TNBC lymph node metastases. Samples were scored on
scales of 0-3 for both intensity and distribution percentage and then added
together (n = 45).
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Figure 4.4 AMPKα1 is expressed in TNBC lymph node metastases.
IHC staining of AMPKα1 in TNBC lymph node metastases. Samples were scored
on scales of 0-3 for both intensity and distribution percentage and then added
together (n = 45).
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Figure 4.5 AMPKα2 is expressed in TNBC lymph node metastases.
IHC staining of AMPKα2 in TNBC lymph node metastases. Samples were scored
on scales of 0-3 for both intensity and distribution percentage and then added
together (n = 45).
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Figure 4.6 Akt2 promotes migratory and invasive phenotypes of TNBC
cells.
(A) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM of siRNA
targeting Akt1 or Akt2. Expression of Akt1, Akt2, ZO-1, Claudin-1, E-cadherin,
Vimentin, β-catenin, and Snail was analyzed by western blot 72h after
transfection. (B) MDA-MB-231 and MDA-MB-468 cells were transfected with 50
nM of siRNA targeting AMPKα1 or AMPKα2. Expression of AMPKα1, AMPKα2,
β-catenin, Snail, ZO-1, E-cadherin, and Zeb1 was analyzed by western blot 72h
after transfection. NTC, Non-targeting control was used as a negative control.
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Figure 4.7 Akt1 and Akt2 suppress apoptosis induction in TNBC cells.
(A) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM siRNA
targeting Akt1 or Akt2. Expression of Akt1, Akt2, and cleaved PARP was
detected with western blot 72h after transfection. (B) MDA-MB-231 cells were
transfected with 50 nM siRNA targeting AMPKα1 or AMPKα2. Expression of
AMPKα1, AMPKα2, and cleaved PARP was detected with western blot 72h after
transfection. (C) MDA-MB-231 and MDA-MB-468 cells were transfected with 50
nM siRNA targeting Akt1 or Akt2. Expression of pAkt, Akt1, Akt2, Bcl-xL, Bcl-2,
Mcl-1, Bim, Bad, and BID was detected with western blot 72h after transfection.
Non-targeting control (NTC) was used as a negative control.
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Figure 4.8 Akt1 and Akt2 promote lung colonization of TNBC cells.
(A) MDA-MB-231-GFP cells were transfected with 50 nM of siRNA targeting Akt1
or Akt2. Cells were collected 48h after transfection and injected intravenously
into NSG mice. MDA-MB-231 lung metastasis was visualized with fluorescence
imaging 28d later. (B) ImageJ was used to quantify overall metastatic burden in
mice lungs. * indicates p<0.05.
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Figure 4.9 AMPKα isoforms do not facilitate lung colonization of TNBC
cells.
(A) MDA-MB-231 cells were transfected with siRNA targeting Akt1, AMPKα1, or
Akt1/AMPKα1. Transfection concentrations were: (1) individual siRNA: 50 nM, (2)
combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM.
Expression of Akt1, AMPKα1, cleaved PARP, and Bim was detected with
western blot 72h after transfection. (B) MDA-MB-231-GFP cells were transfected
with siRNA targeting Akt1, AMPKα1, or Akt1/AMPKα1. Transfection
concentrations were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM
each (100 nM total), and (3) NTC: 100 nM. Cells were collected 48h after
transfection and injected intravenously into NSG mice. MDA-MB-231 lung
metastasis was visualized with fluorescence imaging 40d later. (C) MDA-MB231-GFP cells were transfected with siRNA targeting AMPKα2. Transfection
concentrations were 50 nM for NTC and 50 nM for AMPKα2. Cells were collected
48h after transfection and injected intravenously into NSG mice. MDA-MB-231
lung metastasis was visualized with fluorescence imaging 36d later. Lungs were
subsequently removed and photographed. (D) MDA-MB-231-GFP cells were
transfected with siRNA targeting AMPKα1/2. Transfection concentrations were
100 nM for NTC and 50 nM for AMPKα1/2. Cells were collected 48h after
transfection and injected intravenously into NSG mice. MDA-MB-231 lung
metastasis was visualized with fluorescence imaging 36d later.
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Figure 4.10 Akt1 and Akt2 promote lung colonization of TNBC cells
independent of Akt activity.
(A) MDA-MB-231 cells were treated with 10 μM MK-2206 for 22h. Fresh medium
containing 10 μM MK-2206 was then added for 2h more. Expression of pAkt was
subsequently analyzed with western blot with Akt (pan) and β-actin as loading
controls. (B) MDA-MB-231-GFP cells were treated with 10 μM MK-2206 for 22h.
Fresh medium containing 10 μM MK-2206 was then added for 2h more. Cells
were subsequently collected and injected intravenously into NSG mice. MDAMB-231 lung metastasis was visualized with fluorescence imaging 46d later.
(C) Quantification of green fluorescence intensity from lungs in (B) using ImageJ.
(D) Summary diagram showing that silencing Akt1 or Akt2 prevents TNBC lung
colonization by inducing apoptosis or inhibiting invasion, respectively, while
knockdown of AMPKα1 or AMPKα2 does not impact TNBC lung colonization.

74

CHAPTER 5. CONCLUSIONS
TNBC makes up 15-20% of all breast cancers and is classified by the
absence of the estrogen receptor, the progesterone receptor, and the HER2
protein [3-5]. TNBC is a very aggressive disease that affects a younger patient
population and has a higher metastatic rate than other breast cancers [3-5, 8, 9].
Furthermore, TNBC comprises a diverse group of tumors that includes BL1, BL2,
M, and LAR [11, 17]. For the most part, these tumors have proven refractory to
targeted therapy. Instead, patients generally receive NAC in addition to surgery
and radiotherapy. The NAC standard of care includes an anthracycline, a taxane,
and potentially a DNA alkylating agent, but platinum agents are currently under
investigation and also appear to provide benefit [3, 4, 9, 17, 24]. This regimen is
successful for certain patients, but a subset of TNBC patients have tumors that
are resistant to both NAC and localized therapies [32]. Patients with RD after
receiving NAC are more likely to experience recurrent disease and have lower
survival than those who achieve pCR [8, 13, 39-41, 43]. As a result, there is an
urgent need to develop strategies that can improve treatment in patients who
have RD after receiving NAC. In particular, those with stage II or III TNBC that is
refractory to NAC may benefit from novel therapeutics.
AMPK and Akt are important metabolic regulators that have been
implicated in cancer progression. The purpose of this project was to determine
whether AMPK and Akt can be targeted to enhance TNBC therapy or reduce
TNBC metastasis.
5.1 Role of AMPKα in TNBC – An Apparent Dichotomy
Both AMPKα1 and AMPKα2 were expressed in TNBC patient samples,
PDXs, and cell lines. Moreover, both isoforms promoted G1 cell cycle
progression and cell proliferation potentially through p53 downregulation.
AMPKα1 also facilitated basal and compensatory glycolysis. These findings
indicate that AMPKα1 and AMPKα2 have a tumor promoter role in TNBC.
However, treatment with the AMPKα activator FND-4b induced cell cycle arrest,
suppressed mTOR signaling, and reduced TNBC proliferation. The results from
this study suggest that AMPKα has a tumor suppressor role. Reconciling this
apparent dichotomy is of utmost importance before therapeutics targeting
AMPKα are used in the clinic for treating TNBC. An attempted rationalization is
below.
Under physiological conditions, AMPKα maintains energy homeostasis by
increasing ATP production through glycolysis and fatty acid oxidation [47, 48, 60,
62]. In addition, AMPKα can promote survival in stressful conditions through the
autophagy pathway [45]. These functions ensure that cells remain healthy and
able to proceed through the cell cycle and undergo mitosis. However,
administration of a small molecule activates AMPKα to a supraphysiological level
[54]. When this occurs, AMPKα may sense that the cell desperately needs ATP
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and therefore alter signaling through a wide variety of metabolic pathways.
AMPKα can reduce the rates of fatty acid synthesis and protein synthesis by
inhibiting acetyl CoA carboxylase and mTOR, respectively [47, 48]. However,
anabolic pathways can also control cell cycle progression [54, 111]. For instance,
mTOR controls cyclin D1 levels through eukaryotic translation initiation factor 4Ebinding protein 1 (4E-BP1) [148]. Reduced mTOR signaling could therefore result
in lower levels of cyclin D1 and lead to a G1 cell cycle arrest. Moreover, fatty acid
synthesis is required for cells to progress from the G2 phase into mitosis, and
decreased lipid synthesis could induce arrest at the G2-M checkpoint [54].
Suppressed signaling through anabolic pathways due to supraphysiological
AMPKα activation may overcome AMPKα’s ability to promote cell cycle
progression and instead induce cell cycle arrest.
Another reason why AMPKα activators reduce cellular proliferation may lie
in their respective mechanisms of action. Many such compounds do not activate
AMPKα directly; instead, they induce cellular metabolic damage, which leads to
lower ATP levels and higher AMP levels. These changes in turn induce AMPKα
activation. For instance, 2-deoxyglucose blocks glycolysis while metformin
inhibits the mitochondrial respiratory chain [76]. These metabolic deficiencies will
likely activate other cellular pathways in addition to AMPKα. A recent study has
shown that many common AMPKα activators suppress proliferation in AMPKα
knockdown cells [76]. These findings suggest that other signaling pathways have
a critical role in modulating cellular proliferation in response to metabolic insults.
Moreover, these results call into question the ability of AMPKα activation to
decrease cellular growth. Activation of AMPKα may be better understood as an
indicator of metabolic damage instead of as a primary regulator of cellular
proliferation.
5.2 AMPKα Isoforms Have Different Subcellular Localizations
AMPKα1 was localized in the cytoplasm of TNBC patient samples and
was predominantly found in the cytoplasm of TNBC lymph node metastases.
AMPKα2, however, was mostly found in both the cytoplasm and nucleus in both
the TNBC patient samples and the TNBC lymph node metastases. These
findings indicate that AMPKα2 is preferentially expressed in the nucleus
compared to AMPKα1. Nuclear expression of AMPKα2 has previously been
observed, and AMPKα2 has a nuclear localization sequence [120, 149, 150].
AMPKα1 does not have the same sequence [150]. While further work is needed,
it is possible that AMPKα2 regulates nuclear signaling—potentially controlling
gene expression through the phosphorylation of transcription factors. In TNBC
cells, silencing AMPKα2 led to a less robust reduction in cyclin D1 expression
than AMPKα1 knockdown. However, TNBC cells with AMPKα2 knockdown
proliferated slower than those with AMPKα1 knockdown. This suggests that
AMPKα2 may affect cellular proliferation via other mechanisms that have not
been determined yet. Future studies will need to delineate signaling pathways
that are uniquely controlled by AMPKα2.
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5.3 Targeted AMPKα Therapies Should be Developed
Regardless of mechanism, compounds that activate AMPKα can suppress
cancer cell proliferation and may have a role in future chemotherapeutic
regimens. AMPKα has wide-ranging effects in the body, so it is necessary to
consider the side effects and potential toxicities that accompany prolonged
AMPKα activation. First, AMPKα promotes fatty acid oxidation and prevents
triglyceride synthesis in the liver and adipose tissue [151]. This will mobilize
energy that may be necessary to maintain important bodily functions during
chemotherapy. Next, AMPKα inhibits DNA replication [151]. Supraphysiological
activation of AMPKα could prevent normal cells from successfully undergoing
mitosis. Rapidly proliferating cells, such as hair follicles, may be most susceptible
to this blockade, so a potential side effect is hair loss. Third, activation of AMPKα
has been shown to stimulate food consumption and increase body weight in mice
[151]. Replicating such an effect in TNBC patients may reduce cancer cachexia
and improve treatment outcome. In addition, AMPKα positively regulates
endothelial nitric oxide synthase (eNOS) to ensure that blood flow is maintained
to important organs [151]. Finally, AMPKα can phosphorylate serine residues on
the cystic fibrosis transmembranal conductance regulator (CFTR), a membrane
protein in lung secretory cells that channels chloride ions into and out of a cell
[151]. AMPKα phosphorylates residues that normally keep the chloride channel
closed, and AMPKα activation should prevent a buildup of chloride ions and
mucus within lung cells [151]. Thus, AMPKα activation may provide therapeutic
benefit for patients suffering from cystic fibrosis [151].
Developing therapeutics that selectively target AMPKα in TNBC cells
needs further exploration. Current AMPKα activators have opposite effects in
different parts of the body [151]. For instance, leptin and metformin block AMPKα
activity in the hypothalamus but induce its activation in peripheral tissues [151].
Therefore, administering either agent to a TNBC patient may reduce appetite and
prevent weight gain—potentially worsening the effects of cachexia. Oncologists
should consider how administering metformin will impact a TNBC patient’s ability
to maintain weight throughout therapy. Moreover, ghrelin and cannabinoids
inhibit AMPKα in adipose tissue and the liver but increase its activation in the
hypothalamus [151]. Treatment with a cannabinoid may stimulate appetite and
prevent cachexia in TNBC patients, but this could also interfere with the body’s
ability to generate energy from triglycerides. Decreased energy production may
increase fatigue and drowsiness among TNBC patients. These two examples
indicate why it is imperative to identify novel AMPKα activators that have tissuespecific effects before they are widely used in the clinic for TNBC treatment.
5.4 Reducing Akt1 Expression Sensitizes TNBC to Radiation
Reducing Akt1 expression for stage II and III TNBC patients undergoing
radiotherapy is a novel therapeutic strategy that could enhance the efficacy of
radiation. Improving the effectiveness of radiation therapy in TNBC patients with
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radioresistant tumors should directly reduce recurrence and improve survival.
Moreover, pharmacological suppression of Akt1 expression at the onset of
radiation-induced apoptosis with MK-2206 synergistically promoted apoptosis.
This finding is particularly important because it suggests that radiation therapy
can be potentiated in TNBC patients with administration of a radiosensitizer for
only a short time period. By limiting exposure to pharmacological agents that may
also affect nonmalignant cells, TNBC patients will experience fewer side effects
and find treatment more tolerable. In addition, patients may be able to receive
lower radiation doses, which would likely widen the therapeutic index. Apoptosis
induction occurred between 48h and 72h after radiotherapy in TNBC cells, and
Akt1 suppression 48h after radiation therapy was sufficient to potentiate
radiation-induced apoptosis in vitro. These timepoints will most likely be different
in TNBC patients, so further studies need to be conducted in vivo. In addition,
current radiotherapy regimens utilize a fractionated approach in which radiation is
usually delivered 5 consecutive days for 5 weeks. This protocol differs from the
single-dose approach that was used to examine radiosensitivity. However, a
fractionated approach was able to induce apoptosis 96h after the initial treatment
in TNBC cells. It is likely that reducing Akt1 expression will also induce apoptosis
with the fractionated protocol. Future work will need to determine the optimal
timing to potentiate radiation-induced apoptosis with this strategy.
Enhancing radiotherapy in patients with stage II or III TNBC by reducing
Akt1 expression will also reduce the amount of ionizing radiation (IR) that must
be delivered. Side effects from IR include fatigue, skin irritation, and lymphedema
[152]. For the most part, these side effects should be well tolerated by patients.
However, IR can also contribute to the development of a secondary cancer [153].
The chance of this happening is low, but it is imperative to minimize the risk of an
additional cancer in patients who already have refractory TNBC. Decreasing the
amount of IR that must be administered will directly reduce toxicity and the
probability of a patient getting a second cancer.
Future work should focus on identifying novel agents that can reduce Akt1
expression. This will most likely involve a rational drug design approach that will
include collaborations between cancer biologists, organic chemists, and
computational chemists. Although administration of MK-2206 suppressed Akt1
and enhanced radiation-induced apoptosis, the effects were somewhat mild.
Efforts should now be focused on developing a compound that can reduce Akt1
expression to a similar degree as siRNA knockdown. If that is possible, then it is
likely that such an agent would be able to potentiate radiation-induced apoptosis
to a greater degree than MK-2206. Further in vitro and in vivo studies should be
conducted to analyze the ability of the drug to act as a radiosensitizer in TNBC.
Once a more potent agent has been identified and successfully evaluated, a
clinical trial could also be initiated to establish its safety and efficacy in a target
patient population—such as those with NAC-resistant stage II or III TNBC.
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5.5 Suppressing Akt1 or Akt2 Expression Reduces TNBC Lung Metastasis
Reducing expression of Akt1 and/or Akt2 to suppress metastasis should
be considered as a novel therapeutic strategy for patients with stage II or III
TNBC that is refractory to NAC. Silencing Akt1 or Akt2 reduced lung colonization
by inducing apoptosis or decreasing invasion, respectively. These results
suggest that both Akt1 and Akt2 are key mediators of TNBC metastasis.
However, knockdown of AMPKα1, AMPKα2, or AMPKα1/2 did not impact lung
colonization of TNBC cells. In addition, combined targeting of AMPKα1 and Akt1
did not reduce metastasis more than targeting Akt1 alone. These results suggest
that AMPKα isoforms do not affect TNBC survival during transport or
extravasation through a vessel. Instead, the primary role of AMPKα isoforms on
TNBC metastasis seems to involve growth regulation of cells that have already
colonized distant organs. Administering an Akt suppressor during adjuvant
chemotherapy could prevent distant metastases in patients with non-responsive
TNBC.
Future efforts should focus on identifying and synthesizing
pharmacological agents that can selectively reduce Akt1 or Akt2 expression to a
degree that is similar to genetic knockdown. MK-2206 reduced Akt1 levels and
induced radiosensitivity in TNBC cells, but treatment with this compound was
unable to prevent lung colonization. This may be because a stronger reduction in
Akt1 expression is needed to limit metastatic spread. However, MK-2206’s
inability to reduce TNBC metastasis clearly indicates that the effect is
independent of Akt activity. Developing a more potent suppressor of Akt isoform
expression should follow a similar protocol as that discussed in section 5.4. After
that, it will be vital to test the ability of the compound to reduce distant metastasis
in TNBC patients with stage II or III disease who are refractory to NAC.
5.6 Akt1 and Akt2 Promote TNBC Metastasis Independent of Akt Activity
Silencing either Akt1 or Akt2 reduced TNBC metastatic burden in lung
tissue in a manner that was independent of their kinase activity. As shown in
Figure 4.8C, suppression of Akt1 or Akt2 expression in MDA-MB-231 cells did
not induce a concomitant decrease in pAkt expression. Akt2 knockdown was
associated with an increase in Akt activity. The maintenance of pAkt expression
after Akt isoform knockdown is most likely due to compensatory phosphorylation
of the isoform that is still present at basal levels. Other studies have also found
that Akt has a non-kinase role [144, 145]. Akt1 decreases toll-like receptor
signaling in an Akt-independent manner [144]. In addition, Akt promotes survival
of cancer cells in a fashion that is independent of its kinase function and instead
depends on its pleckstrin homology (PH) domain [145]. Akt1 and Akt2 may also
rely on the PH domain to facilitate survival of TNBC cells, but further work will be
needed to establish the underlying mechanisms.
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5.7 Potential Drug Delivery Method for TNBC
Pharmacological agents that selectively activate AMPKα or reduce
expression of Akt1 or Akt2 should be developed and tested in TNBC patients.
However, identifying targeted therapies has been difficult because TNBC lacks
hormone receptors or HER2 overexpression. Prior work has identified that mRNA
for folate receptor α (FRα) is significantly higher in TNBC than in other breast
cancer subtypes [154]. Novel compounds that activate AMPKα or reduce Akt
isoform expression could be conjugated to folate, which should preferentially
target TNBC cells that have high expression of FRα. Benign cells that have lower
levels of FRα should largely be spared. The drug conjugate will be transported
into the cancer cells through receptor-mediated endocytosis [155]. Folatetargeted therapy is under investigation with vintafolide, which is composed of
desacetylvinblastine monohydrazide (DAVLBH) conjugated to folate [155].
DAVLBH is a derivative of vinblastine and is released into tumor cells where it
suppresses cell division and promotes cell death [155]. Vinblastine has been
analyzed in phase II and III clinical trials in ovarian and lung cancers [155]. If
agents that activate AMPKα or reduce Akt isoform expression can be conjugated
to folate, then it is likely that they can be selectively targeted to TNBC cells.
5.8 Final Thoughts
TNBC patients who have RD after administration of NAC desperately
need novel therapeutic interventions. In particular, such strategies could be
targeted toward TNBC patients with stage II or III disease that is refractory to
NAC. AMPK and Akt are important regulators of cellular metabolism that can also
affect cell cycle progression and proliferation. As a result, these pathways are
prime targets to enhance current therapeutic regimens for TNBC patients. AMPK
activators can reduce proliferation of cancer cells. FND-4b is a novel compound
that can activate AMPK, suppress growth, and induce apoptosis at low
micromolar concentrations in TNBC cells. Future work could analyze whether
AMPK activators can enhance adjuvant or neoadjuvant chemotherapy. Targeting
Akt signaling may also enhance TNBC therapy and improve patient survival.
Silencing Akt1 sensitized TNBC cells to radiation-induced apoptosis, and
pharmacological reduction of Akt1 expression with MK-2206 48h after
radiotherapy synergistically promoted apoptosis. These findings indicate that
there may be clinical benefit in reducing Akt1 expression during radiation
treatment. In addition, knockdown of Akt1 or Akt2 dramatically decreased TNBC
lung colonization in a kinase-independent manner. Suppressing TNBC
metastasis may prevent distant recurrence while treatment strategies are
adjusted for patients with RD. Clinical trials could further analyze the effects of
AMPK activation and Akt isoform suppression in TNBC patients with resistant
disease. Taken together, these studies identify promising approaches that may
improve therapeutic response among TNBC patients whose tumors are
refractory to NAC—especially those with resistant stage II or III TNBC.
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